PLoS ONE
Home Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches
Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches
Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches

Competing Interests: The authors have declared that no competing interests exist.

Article Type: research-article Article History
Abstract

Among various delivery systems for vaccine and drug delivery, cell-penetrating peptides (CPPs) have been known as a potent delivery system because of their capability to penetrate cell membranes and deliver some types of cargoes into cells. Several CPPs were found in the proteome of viruses such as Tat originated from human immunodeficiency virus-1 (HIV-1), and VP22 derived from herpes simplex virus-1 (HSV-1). In the current study, a wide-range of CPPs was identified in the proteome of SARS-CoV-2, a new member of coronaviruses family, using in silico analyses. These CPPs may play a main role for high penetration of virus into cells and infection of host. At first, we submitted the proteome of SARS-CoV-2 to CellPPD web server that resulted in a huge number of CPPs with ten residues in length. Afterward, we submitted the predicted CPPs to C2Pred web server for evaluation of the probability of each peptide. Then, the uptake efficiency of each peptide was investigated using CPPred-RF and MLCPP web servers. Next, the physicochemical properties of the predicted CPPs including net charge, theoretical isoelectric point (pI), amphipathicity, molecular weight, and water solubility were calculated using protparam and pepcalc tools. In addition, the probability of membrane binding potential and cellular localization of each CPP were estimated by Boman index using APD3 web server, D factor, and TMHMM web server. On the other hand, the immunogenicity, toxicity, allergenicity, hemolytic potency, and half-life of CPPs were predicted using various web servers. Finally, the tertiary structure and the helical wheel projection of some CPPs were predicted by PEP-FOLD3 and Heliquest web servers, respectively. These CPPs were divided into: a) CPP containing tumor homing motif (RGD) and/or tumor penetrating motif (RXXR); b) CPP with the highest Boman index; c) CPP with high half-life (~100 hour) in mammalian cells, and d) CPP with +5.00 net charge. Based on the results, we found a large number of novel CPPs with various features. Some of these CPPs possess tumor-specific motifs which can be evaluated in cancer therapy. Furthermore, the novel and potent CPPs derived from SARS-CoV-2 may be used alone or conjugated to some sequences such as nuclear localization sequence (NLS) for vaccine and drug delivery.

Kardani,Bolhassani,and Bhattacharjya: Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches

Introduction

Therapeutic and preventive vaccines are promising approaches to solve health issues globally [1]. Although there are several vaccines for saving millions of lives till now such as vaccines against rubella, mumps, varicella, rotavirus, human papillomavirus (HPV) and hepatitis B virus (HBV), it is required to develop effective vaccines against other pathogens which are incurable and unprotectable [2,3]. In this line, development of effective and novel delivery systems is vital for delivery of vaccine components into cells. In general, delivery systems can be used to transfer different biomolecules into cells including nanoparticles [4], polymers [5], chitosan [6], liposome [7], physical tools [8], and cell penetrating peptides (CPPs) [9,10]. The current focus of developing a novel delivery system has moved to peptide-based delivery systems known as CPPs [11]. CPPs contain 5–50 amino acids in length which can enter cell membranes efficiently and deliver a wide range of cargoes including peptides, proteins, nanoparticles and nucleic acids into cells [12,13]. After discovery of the first CPP, Tat peptide (originated from human immunodeficiency virus type-1 (HIV-1) trans-activating regulatory (Tat) protein), a rapid growth of new CPPs has occurred [14]. The CPPs are natural (e.g., CyLoP-1) or synthetic (e.g., oligoarginine) peptides. These short peptides are heterogeneous in sequence and structure, and can be delivered through endocytosis or direct penetration [1,10,1517]. The mechanism of internalization depends on diverse factors such as CPP sequence, cell type, CPP concentration, temperature, incubation time, and type of cargo [18]. Up to now, a large number of CPPs have been recognized but some of them showed low uptake [19]. The studies demonstrated that prediction of CPPs by bioinformatics tools prior to lab-based experiments could save time and money [20]. For instance, machine-learning-based algorithms permit users to predict CPPs from large sequence data/ proteome. In prediction methods, machine learning models utilize various algorithms including neural network (NN) [21,22], kernel extreme learning machine [23,24], random forest (RF) [25], and support vector machine (SVM) [26,27].

In December 2019, a new member of the coronavirus family was found which firstly named as 2019-nCoV. Then, on February 11, 2020, its name was changed to Coronavirus Disease-2019 (COVID-19) or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [28]. SARS-CoV-2 is an enveloped positive single-strand RNA virus that has 10 open reading frames (ORFs). ORF1ab is about 66.66% of virus genome which encodes two large polypeptides such as pp1a and pp1ab. Meanwhile, the ORF2-10 is about 33.33% of virus genome. SARS-CoV-2 genome encodes 28 proteins which are classified into three various classes such as structural proteins, non-structural proteins (nsp), and accessory proteins. The structural proteins are spike (S), nucleoprotein (N), membrane (M), and envelope (E) proteins that form the virus particles. In addition, the non-structural proteins (e.g., nsp1-nsp16) are generated only during the translation of virus RNA in the infected host cell. The accessory proteins possess crucial functions in the assembly, virulence and pathogenesis of the virus [28,29].

Previously, several CPPs were derived from viruses such as Tat (from HIV-1 transcriptional activator protein), C105Y (from HIV-1 glycoprotein 41), MPG (from HIV-1 glycoprotein 41 conjugated to nuclear localization sequence (NLS) from simian virus 40 (SV40)), Pep-1 (from HIV-1 reverse transcriptase conjugated to SV40 NLS), pepR and pepM (originated from Dengue virus), VP22 (originated from Herpes simplex virus (HSV)-1) [14,3034]. Up to now, no complete report has been available on CPPs derived from total proteins of MERS-CoV, SARS-CoV and SARS-CoV-2. Few studies indicated that some peptides of SARS-CoV spike glycoprotein are responsible for membrane fusion or membrane binding activity. For example, the upstream region of the heptad repeat1 (HR1) (residues 892–972) in S2 domain of SARS-CoV spike glycoprotein was involved in membrane fusion. Moreover, some scientists have recognized membrane binding peptides and membrane fusogenic peptides or potential fusion peptides from the upstream region of HR1 (residues 758–890) [35]. Indeed, an efficient membrane fusion mechanism between host cell and SARS-CoV-2 can be responsible for virus infection. Sequence comparison of S protein domains between SARS-CoV-2 and SARS-CoV-1 showed high level of conservation for both S1 and S2 domains. However, variation in the fusogenic regions of S2 domain was observed between SARS-CoV-2 and SARS-CoV-1 [3638]. Hence, due to high potency of SARS-CoV-2 to spread and infect people, we decided to investigate new and potent CPPs in the proteome of this newly isolated virus using in silico approaches.

Materials and methods

Study design

The current study has several main steps to find and characterize novel and potent CPPs as a vaccine and drug delivery system. The flowchart of overall prediction and analysis procedure was illustrated in S1 Fig.

Identification of potential SARS-CoV-2-derived CPPs

Cell penetrating or non-cell penetrating peptides (CPP or non-CPP) could be predicted in the proteome of SARS-CoV-2 using bioinformatics approaches. Hence, to explore novel CPPs, our reference sequence was Wuhan-Hu-1 with GenBank accession number MN908947.3. This strain was isolated from a patient in Wuhan, china. The phylogenetic analysis of whole viral genome contain 29,903 nucleotides that has 89.1% nucleotide similarity to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) which formerly had been recognized in bats [39].

At first, CellPPD web server (https://webs.iiitd.edu.in/raghava/cellppd/index.html) was applied to determine the cell penetrating peptides. CellPPD is a support vector machine (SVM)-based web server [40,41]. To utilize this web server, the sequences of Spike (S) protein (GenBank ID: QHD43416.1), Membrane (M) glycoprotein (GenBank ID: QHD43419.1), Nucleocapsid (N) phosphoprotein (GenBank ID: QHD43423.2), Envelope (E) protein (GenBank ID: QHD43418.1), Orf1ab polyprotein (GenBank ID: QHD43415.1), ORF3a protein (GenBank ID: QHD43417.1), ORF6 protein (GenBank ID: QHD43420.1), ORF7a protein (GenBank ID: QHD43421.1), ORF8 protein (GenBank ID: QHD43422.1), and ORF10 protein (GenBank ID: QHI42199.1) were submitted to protein scanning tool with default threshold of the SVM-based prediction method (SVM threshold was set at 0.0). Moreover, Tang and colleagues [42] developed a method with an overall prediction accuracy of 83.6%; hence, they established C2Pred web server (http://lin-group.cn/server/C2Pred) to investigate the CPP probability of each peptide.

Uptake efficiency analysis of the identified CPPs

In next step, to evaluate the uptake efficiency of the identified CPPs from previous step, two web servers including CPPred-RF (http://server.malab.cn/CPPred-RF/), and MLCPP (http://www.thegleelab.org/MLCPP/) were used. For this purpose, all of the detected CPPs using CellPPD web server were submitted to these web servers. CPPred-RF is a sequence-based predictor for identifying CPPs and their uptake efficiency. In addition, CPPred-RF built a two-layer prediction framework according to the random forest (RF) algorithm [43]. Manavalan et al. established a two-layer prediction framework termed as machine-learning-based prediction of cell-penetrating peptide (MLCPPs). The first-layer predicts that a submitted peptide is categorized as a CPP or non-CPP. Meanwhile, the second-layer predicts the uptake efficiency of the predicted CPPs [44].

Peptides property calculation

It is crucial to compute the physicochemical properties of peptides for predicting and designing novel and potent CPPs. Therefore, to achieve this aim, we calculated various physicochemical features of CPPs such as net charge, theoretical isoelectric point (pI), amphipathicity, molecular weight (MW), water solubility, hydrophobicity (H), hydrophobicity ratio, and polar-, non-polar-, uncharged- and charged residues. To calculate net charge, theoretical pI, and amphipathicity, CellPPD web server (https://webs.iiitd.edu.in/raghava/cellppd/index.html) was utilized. In addition, protparam tool (https://web.expasy.org/protparam/) was used to compute molecular weight of CPPs. Furthermore, to obtain the water solubility of peptides, Peptide property calculator (PepCalc) (https://pepcalc.com/) was applied. Also, hydrophobicity (H), and polar-, non-polar-, uncharged- and charged residues were estimated using Heliquest web server (https://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParams.py).

Evaluation of membrane-binding ability of CPPs

In order to investigate the potential of binding peptides to membrane, two different methods were utilized. At first, we evaluated the Boman index or protein-binding potential using APD3 web server (http://aps.unmc.edu/AP/prediction/prediction_main.php). The Boman index is the sum of solubility values for all presented amino acids in a peptide sequence and illustrates the potential of a peptide for binding to the membrane or other proteins [45]. Secondly, to evaluate the membrane-binding potential of each peptide, the discrimination factor (D) was calculated [46]. For this purpose, we used Heliquest web server (https://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParams.py) to obtain hydrophobic moment (μH). After determination of hydrophobic moment and also net charge (Z), the D factor was calculated according to the following equation: D = 0.944(<μH>) + 0.33(Z).

In addition, TMHMM web server (http://www.cbs.dtu.dk/services/TMHMM/) was utilized to investigate the cellular localization of CPPs [47]. This web server analyzes the probability of binding a peptide to the bacterial cell membrane (BCM) which possesses negative charge.

Assessment of the immunogenicity

Immunogenicity of the CPPs is one of their disadvantages. It was confirmed that peptides could induce immunologic responses in vivo, resulting in allergic reactions. The existence of peptides in body can stimulate the generation of antibodies which may neutralize therapeutic effects and reduce their efficacy [48, 49]. Hence, to assess the immunogenicity of CPPs, each peptide was submitted to IEDB Immunogenicity Predictor (http://tools.iedb.org/immunogenicity/) [50].

Determination of toxicity and allergenicity

To investigate the toxicity and allergenicity of CPPs, each peptide was submitted to ToxinPred web server (https://webs.iiitd.edu.in/raghava/toxinpred/algo.php), and AllerTop (https://www.ddg-pharmfac.net/AllerTOP/) and AllergenFP (http://ddg-pharmfac.net/AllergenFP/) web servers, respectively [5153].

Estimation of hemolytic potency and half-life

The hemolytic property of peptides was predicted by HemoPI using SVM-based method (https://webs.iiitd.edu.in/raghava/hemopi/design.php). Furthermore, the half-life in E.coli and in mammalian cell was calculated using ProtLifePred web server based on N-end rule (http://protein-n-end-rule.leadhoster.com/) [54].

Prediction of structure

Three dimensional (3D) structure of some predicted CPPs was analyzed by de novo peptide structure prediction server (PEP-FOLD3) (https://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD3/). PEP-FOLD3 is a de novo method that predicts peptide structures using amino acid sequences. This approach determines the conformation of four consecutive amino acid residues according to structural alphabet (SA) letters [55]. Additionally, the helical wheel diagram of CPPs was defined by Schiffer Edmundson wheel modelling using Heliquest web server (https://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParams.py) [46].

Results

Identification of potential SARS-CoV-2-derived CPPs

To obtain cell penetrating peptides in the proteome of SARS-CoV-2, the sequences of S protein, M glycoprotein, N phosphoprotein, E protein, Orf1ab polyprotein, and ORF3a, ORF6, ORF7a, ORF8 and ORF10 proteins were submitted to protein scanning tools of CellPPD web server. Then, we applied C2Pred web server to achieve the CPP probability of peptides. All of the detected CPPs, and their SVM scores and probability scores were listed in Table 1. No CPP was found in E protein, and only one CPP was identified in ORF6. Meanwhile, Orf1ab had the most CPPs in its proteome. C2pred web server identifies peptides lower than 0.5 as non-CPPs, and peptides greater than 0.5 as CPPs. Although, some peptides were predicted as CPPs by CellPPD, but C2Pred detected them as non-CPPs. For instance, DMSKFPLKLR peptide derived from Orf1ab polyprotein was predicted as CPP by CellPPD with SVM score of 0.11, while C2Pred determined this peptide as non-CPP with score 0.167688.

Table 1
Predicted CPPs and their uptake efficiency using various web servers.
EpitopeCellPPD (SVM score)CPP Probability score by C2Pred*Uptake efficiency by MLCPPUptake efficiency by CPPred-RF
S protein
NLTTRTQLPP0.030.549136LowHigh
RFQTLLALHR0.110.924753LowHigh
YLQPRTFLLK0.050.745663LowHigh
SVYAWNRKRI0.120.542719LowHigh
YAWNRKRISN0.210.581372LowHigh
AWNRKRISNC0.100.581372LowHigh
WNRKRISNCV0.070.422121LowHigh
RQIAPGQTGK0.050.480859LowHigh
YNYLYRLFRK0.100.434133HighHigh
YLYRLFRKSN0.170.323746HighHigh
YRLFRKSNLK0.180.651294LowHigh
RLFRKSNLKP0.180.633622LowHigh
RKSNLKPFER0.140.800554LowHigh
KKSTNLVKNK0.330.588285LowHigh
KSTNLVKNKC0.060.527724LowHigh
HADQLTPTWR0.000.545188LowNon-CPP
YQTQTNSPRR0.110.149319LowHigh
TQTNSPRRAR0.110.143146LowHigh
TNSPRRARSV0.160.142480LowHigh
NSPRRARSVA0.140.108221LowHigh
PRRARSVASQ0.170.236319LowHigh
KQIYKTPPIK0.460.944703LowHigh
SQILPDPSKP0.030.906582LowHigh
RLITGRLQSL0.210.663600LowHigh
M protein
NRNRFLYIIK0.020.220554LowHigh
RNRFLYIIKL0.180.114117LowHigh
YIIKLIFLWL0.010.669640LowHigh
KLIFLWLLWP0.310.709344LowHigh
FIASFRLFAR0.100.421173LowHigh
ASFRLFARTR0.200.594022LowHigh
SFRLFARTRS0.060.553645LowHigh
FRLFARTRSM0.210.385465LowHigh
RLFARTRSMW0.280.383433LowHigh
FARTRSMWSF0.040.463913LowHigh
HGTILTRPLL0.030.430916LowHigh
GAVILRGHLR0.130.223997HighHigh
RIAGHHLGRC0.020.243928LowHigh
YSRYRIGNYK0.050.897477LowHigh
N protein
PQNQRNAPRI0.090.413323LowHigh
ERSGARSKQR0.060.261718LowHigh
RSGARSKQRR0.540.292041LowHigh
SGARSKQRRP0.250.300551LowHigh
GARSKQRRPQ0.400.250417LowHigh
ARSKQRRPQG0.170.298689LowHigh
RSKQRRPQGL0.360.192042LowHigh
SKQRRPQGLP0.060.164110LowHigh
KQRRPQGLPN0.180.206509LowHigh
RRPQGLPNNT0.120.216779LowHigh
QIGYYRRATR0.090.531651LowHigh
IGYYRRATRR0.230.604819LowHigh
GYYRRATRRI0.290.965070LowHigh
YYRRATRRIR0.580.952696LowHigh
YRRATRRIRG0.590.935039LowHigh
RRATRRIRGG0.560.939794LowHigh
RATRRIRGGD0.330.924855LowHigh
TRRIRGGDGK0.100.369598LowHigh
RIRGGDGKMK0.110.250269LowHigh
GKMKDLSPRW0.020.735642LowHigh
SQASSRSSSR0.050.677066LowHigh
ASSRSSSRSR0.170.304528LowHigh
SSRSSSRSRN0.090.304528LowHigh
SRSSSRSRNS0.140.297448LowHigh
RSSSRSRNSS0.120.432735LowHigh
SSSRSRNSSR0.130.315140LowHigh
SSRSRNSSRN0.100.315140LowHigh
RSRNSSRNST0.040.359073LowHigh
GSSRGTSPAR0.060.716403LowHigh
AALALLLLDR0.140.898706LowHigh
ALALLLLDRL0.050.895190LowHigh
KKSAAEASKK0.330.730535LowHigh
KSAAEASKKP0.130.669679LowHigh
SAAEASKKPR0.060.669679LowHigh
AAEASKKPRQ0.100.963042LowHigh
AEASKKPRQK0.150.96509LowHigh
EASKKPRQKR0.340.988105LowHigh
ASKKPRQKRT0.280.947786LowHigh
SKKPRQKRTA0.320.947786LowHigh
KKPRQKRTAT0.470.947786LowHigh
KPRQKRTATK0.420.941370LowHigh
PRQKRTATKA0.230.936878LowHigh
RQKRTATKAY0.130.936878LowHigh
RQGTDYKHWP0.020.249058LowHigh
FPPTEPKKDK0.040.937092LowNon-CPP
PPTEPKKDKK0.120.954110LowHigh
PTEPKKDKKK0.200.965728LowHigh
TEPKKDKKKK0.510.972132LowHigh
EPKKDKKKKA0.350.969009LowHigh
PKKDKKKKAD0.280.736106LowHigh
KKDKKKKADE0.260.275127LowHigh
TQALPQRQKK0.110.378326LowHigh
ALPQRQKKQQ0.170.715403LowHigh
ORF3a
SASKIITLKK0.070.666607LowHigh
ASKIITLKKR0.190.975854LowHigh
SKIITLKKRW0.310.977206LowHigh
KIITLKKRWQ0.560.977206LowHigh
IITLKKRWQL0.040.981679LowHigh
KKRWQLALSK0.470.908996LowHigh
KRWQLALSKG0.310.711236LowHigh
VRIIMRLWLC0.110.512905LowHigh
RIIMRLWLCW0.250.512905LowHigh
IIMRLWLCWK0.140.584110LowHigh
IMRLWLCWKC0.060.584110HighHigh
MRLWLCWKCR0.170.584110HighHigh
RLWLCWKCRS0.220.578205HighHigh
LWLCWKCRSK0.280.516957HighHigh
WLCWKCRSKN0.120.456487HighHigh
LCWKCRSKNP0.160.456487HighHigh
CWKCRSKNPL0.140.815386HighHigh
KCRSKNPLLY0.100.172543LowHigh
Orf1ab
IKRSDARTAP0.000.611515LowHigh
KRSDARTAPH0.080.611515LowHigh
PVAYRKVLLR0.050.395891HighHigh
VAYRKVLLRK0.070.461402HighHigh
AYRKVLLRKN0.130.873577LowHigh
YRKVLLRKNG0.050.873577LowHigh
RKVLLRKNGN0.140.892119LowHigh
KVLLRKNGNK0.010.921012LowHigh
FEIKLAKKFD0.090.877125LowHigh
KTIQPRVEKK0.390.961264LowHigh
TIQPRVEKKK0.130.954110LowHigh
IQPRVEKKKL0.130.953833LowHigh
SGLKTILRKG0.020.624757LowHigh
LKTILRKGGR0.240.808425LowHigh
KTILRKGGRT0.150.805867LowHigh
GNFKVTKGKA0.030.385736LowHigh
FKVTKGKAKK0.350.445305LowHigh
KVTKGKAKKG0.260.339767LowHigh
KGKAKKGAWN0.070.184903LowHigh
GGAKLKALNL0.040.430832LowHigh
SKGLYRKCVK0.090.145729LowHigh
KGLYRKCVKS0.070.145729LowHigh
GLYRKCVKSR0.340.274849LowHigh
GLLMPLKAPK0.090.427961LowHigh
QRKQDDKKIK0.150.861718LowHigh
RKQDDKKIKA0.170.976533LowHigh
KQDDKKIKAC0.070.318404LowHigh
DITFLKKDAP0.030.682254LowNon-CPP
MLAKALRKVP0.280.671110HighHigh
LAKALRKVPT0.080.671110LowHigh
EAKTVLKKCK0.130.717688LowHigh
AKTVLKKCKS0.130.717688LowHigh
KTVLKKCKSA0.220.546244LowHigh
KSAFYILPSI0.000.108440LowHigh
KAIVSTIQRK0.080.204524LowHigh
STIQRKYKGI0.070.433511LowHigh
TIQRKYKGIK0.130.433511LowHigh
IQRKYKGIKI0.080.433511LowHigh
GARFYFYTSK0.040.178363LowHigh
ARYMRSLKVP0.060.471501LowHigh
GIEFLKRGDK0.080.224238LowHigh
DNLKTLLSLR0.030.361469HighNon-CPP
YMSALNHTKK0.050.330689LowHigh
SALNHTKKWK0.120.709364LowHigh
ALNHTKKWKY0.100.888647LowHigh
LNHTKKWKYP0.140.913973LowHigh
NHTKKWKYPQ0.100.678789LowHigh
HTKKWKYPQV0.040.303493LowNon-CPP
KKPASRELKV0.140.769021LowHigh
KPASRELKVT0.070.743805LowHigh
YTPSFKKGAK0.080.164140LowHigh
PSFKKGAKLL0.000.210028LowHigh
FKKGAKLLHK0.160.308486LowHigh
KKGAKLLHKP0.480.308486LowHigh
KGAKLLHKPI0.320.261312LowHigh
WCIRCLWSTK0.120.727461HighHigh
CIRCLWSTKP0.200.727461LowHigh
ANYAKPFLNK0.010.474322LowHigh
TNIVTRCLNR0.010.309069LowHigh
CTFTRSTNSR0.020.513802LowHigh
TCMMCYKRNR0.010.331608HighHigh
MCYKRNRATR0.250.936560LowHigh
CYKRNRATRV0.030.936560LowHigh
YKRNRATRVE0.000.936560LowHigh
KRNRATRVEC0.180.532289LowHigh
RNRATRVECT0.060.325111LowHigh
RDLSLQFKRP0.170.903779LowHigh
SLQFKRPINP0.140.353192LowHigh
HNIALIWNVK0.010.377627LowHigh
LSEQLRKQIR0.040.269638LowHigh
QLRKQIRSAA0.030.615417LowHigh
LRKQIRSAAK0.020.718721LowHigh
RKQIRSAAKK0.300.751730LowHigh
KQIRSAAKKN0.380.729912LowHigh
QIRSAAKKNN0.110.729912LowHigh
AAKKNNLPFK0.090.933084LowHigh
KKNNLPFKLT0.040.938618LowHigh
NNWLKQLIKV0.010.793676HighHigh
LAYYFMRFRR0.040.301382LowHigh
AYYFMRFRRA0.050.289065LowHigh
YYFMRFRRAF0.080.182381HighHigh
FMRFRRAFGE0.050.167797HighHigh
MRFRRAFGEY0.050.167797HighHigh
KEMYLKLRSD0.020.354324LowHigh
YNRYLALYNK0.030.241742HighHigh
RYLALYNKYK0.030.232393HighHigh
FRKMAFPSGK0.030.318037LowHigh
TANPKTPKYK0.150.944703LowHigh
ANPKTPKYKF0.030.944703LowHigh
PKTPKYKFVR0.120.944703LowHigh
KTPKYKFVRI0.100.917400LowHigh
RWFLNRFTTT0.020.601321LowHigh
FQSAVKRTIK0.080.586710LowHigh
SEVVLKKLKK0.240.204172LowHigh
VVLKKLKKSL0.090.270145LowHigh
VLKKLKKSLN0.120.910975LowHigh
KKLKKSLNVA0.150.190690LowHigh
DAAMQRKLEK0.000.372134LowHigh
AAMQRKLEKM0.010.372134LowHigh
MQRKLEKMAD0.160.525121LowHigh
YKQARSEDKR0.020.246035LowHigh
KQARSEDKRA0.130.242658LowHigh
QARSEDKRAK0.050.242658LowHigh
MLFTMLRKLD0.050.894360LowNon-CPP
QDLKWARFPK0.020.860963LowHigh
DLKWARFPKS0.080.860963LowNon-CPP
LKWARFPKSD0.220.397145LowHigh
KGFCDLKGKY0.060.207285LowHigh
GVSAARLTPC0.030.277471LowHigh
GFAKFLKTNC0.010.119116LowNon-CPP
KTNCCRFQEK0.080.481756LowHigh
PHISRQRLTK0.280.636709LowHigh
HISRQRLTKY0.240.636709LowHigh
ISRQRLTKYT0.110.636709LowHigh
SRQRLTKYTM0.010.835148LowHigh
RQRLTKYTMA0.110.878279LowHigh
GERVRQALLK0.090.849631LowHigh
RVRQALLKTV0.090.932330HighHigh
KPYIKWDLLK0.010.876722LowHigh
RLKLFDRYFK0.050.261079LowHigh
KLFDRYFKYW0.040.219406HighNon-CPP
FPFNKWGKAR0.020.889091LowHigh
KWGKARLYYD0.100.289722LowHigh
YAISAKNRAR0.030.154021LowHigh
AISAKNRART0.050.241258LowHigh
KNRARTVAGV0.120.254056LowHigh
NRQFHQKLLK0.140.872914LowHigh
RQFHQKLLKS0.060.938861LowHigh
RIMASLVLAR0.050.515705HighHigh
RNLQHRLYEC0.080.165926LowNon-CPP
RLYECLYRNR0.150.219346LowHigh
SLRCGACIRR0.100.297578HighHigh
RCGACIRRPF0.150.288701HighHigh
CGACIRRPFL0.060.282884HighHigh
GACIRRPFLC0.190.252159HighHigh
ACIRRPFLCC0.110.249754HighHigh
CIRRPFLCCK0.310.306758HighHigh
IRRPFLCCKC0.110.355792HighHigh
RRPFLCCKCC0.180.274986HighHigh
MSYYCKSHKP0.010.306949LowHigh
ANTCTERLKL0.020.144577LowHigh
SWEVGKPRPP0.020.577246LowHigh
VGKPRPPLNR0.110.233226LowHigh
GKPRPPLNRN0.160.742499LowHigh
KALKYLPIDK0.200.613457LowHigh
DKCSRIIPAR0.010.588037LowHigh
KCSRIIPARA0.050.577426LowHigh
CSRIIPARAR0.070.565072LowHigh
SRIIPARARV0.110.783032LowHigh
RIIPARARVE0.170.441924LowHigh
SVVNARLRAK0.040.107521LowHigh
VVNARLRAKH0.100.101852LowHigh
VNARLRAKHY0.080.351672LowHigh
NARLRAKHYV0.130.942607LowHigh
PAPRTLLTKG0.100.701705LowHigh
APRTLLTKGT0.020.414738LowHigh
FNSVCRLMKT0.010.084142LowNon-CPP
FLGTCRRCPA0.090.153800HighHigh
DNKLKAHKDK0.050.454919LowHigh
KLKAHKDKSA0.220.624144LowHigh
FLTRNPAWRK0.170.889087LowHigh
RNPAWRKAVF0.180.548965LowHigh
GIPKDMTYRR0.060.265085LowHigh
DMTYRRLISM0.100.234218LowNon-CPP
GNPKAIKCVP0.050.253610LowHigh
WNTFTRLQSL0.060.961510LowNon-CPP
ELWAKRNIKP0.060.982818LowHigh
LWAKRNIKPV0.010.982818LowHigh
WAKRNIKPVP0.170.862586LowHigh
RNIKPVPEVK0.050.642094LowHigh
LLIGLAKRFK0.190.367884HighHigh
GLAKRFKESP0.180.908642LowHigh
KMQRMLLEKC0.170.500000HighHigh
VLRQWLPTGT0.000.407571LowHigh
DMSKFPLKLR0.110.167688HighHigh
MSKFPLKLRG0.020.319169LowHigh
SKFPLKLRGT0.090.463853LowHigh
KFPLKLRGTA0.010.463853LowHigh
MILSLLSKGR0.020.290394LowHigh
LLSKGRLIIR0.080.570179HighHigh
GRLIIRENNR0.030.864554LowHigh
RLIIRENNRV0.030.930275LowHigh
ORF6
LIIKNLSKSL0.030.692987LowHigh
ORF7a
HVYQLRARSV0.000.333973LowHigh
QLRARSVSPK0.180.788277LowHigh
RARSVSPKLF0.060.540759LowHigh
RSVSPKLFIR0.030.387766LowHigh
ITLCFTLKRK0.000.781141HighHigh
TLCFTLKRKT0.170.809793LowHigh
LCFTLKRKTE0.010.809793LowHigh
ORF8
SKWYIRVGAR0.060.354214LowHigh
KWYIRVGARK0.150.337595LowHigh
YIRVGARKSA0.130.276083LowHigh

* Higher scores show more possibility of cell-penetrating potential.

Uptake efficiency analysis of the identified CPPs

The uptake efficiency of the predicted CPPs was evaluated using two different web servers such as CPPred-RF and MLCPP. These web servers classify CPPs in two categories: high or low uptake efficiency (Table 1).

Calculation of peptide properties

Various physicochemical characteristics of peptides were recognized by diverse web servers such as net charge, pI, MW, amphipathicity, water solubility, hydrophobicity, hydrophobicity ratio, and polar-, non-polar-, uncharged- and charged residues. For instance, a cationic CPP can bind to cell membrane (with negative charge), then can penetrate and deliver cargoes into cells [9]. All of the physicochemical properties of CPPs were determined in Table 2.

Table 2
The properties of peptides determined by diverse web servers and tools.
EpitopeNet chargepIAmphipathicityMWWater solubilityHydrophobicity (H)Hydrophobic ratio by APDPolar residues + GLY (n/%)Nonpolar residues (n/%)Uncharged residues + GLYCharged residues
S protein
NLTTRTQLPP1.0010.110.371140.31Poor0.37920%6/60.004/40.00GLN 1, THR 3, ASN 1, GLY 0ARG 1
RFQTLLALHR2.5012.010.761254.50Poor0.53550%5/50.005/50.00GLN 1, HIS 1, THR 1, GLY 0ARG 2
YLQPRTFLLK2.0010.010.741278.56Poor0.66140%4/40.006/60.00GLN 1, THR 1, GLY 0LYS 1, ARG 1
SVYAWNRKRI3.0011.010.861292.51Good0.28940%5/50.005/50.00SER 1, ASN 1, GLY 0LYS 1, ARG 2
YAWNRKRISN3.0011.010.861307.48Good0.10730%6/60.004/40.00SER 1, ASN 2, GLY 0LYS 1, ARG 2
AWNRKRISNC3.0010.870.861247.45Good0.16540%6/60.004/40.00SER 1, ASN 2, GLY 0LYS 1, ARG 2
WNRKRISNCV3.0010.870.861275.50Good0.25640%6/60.004/40.00SER 1, ASN 2, GLY 0LYS 1, ARG 2
RQIAPGQTGK2.0011.010.861055.20Good0.06520%7/70.003/30.00GLN 2, THR 1, GLY 2LYS 1, ARG 1
YNYLYRLFRK3.0010.000.861435.69Good0.44630%4/40.006/60.00ASN 1, GLY 0LYS 1, ARG 2
YLYRLFRKSN3.0010.290.861435.69Good0.34630%5/50.005/50.00SER 1, ASN 1, GLY 0LYS 1, ARG 2
YRLFRKSNLK4.0011.101.221324.59Good0.15130%6/60.004/40.00SER 1, ASN 1, GLY 0LYS 2, ARG 2
RLFRKSNLKP4.0012.021.221258.53Good0.12730%6/60.004/40.00SER 1, ASN 1, GLY 0LYS 2, ARG 2
RKSNLKPFER3.0011.011.351274.49Good-0.10720%7/70.003/30.00SER 1, ASN 1, GLY 0LYS 2, ARG 2, GLU 1
KKSTNLVKNK4.0010.491.471159.40Good-0.20220%8/80.002/20.00SER 1, THR 1, ASN 2, GLY 0LYS 4
KSTNLVKNKC3.009.811.101134.37Good0.05130%7/70.003/30.00SER 1, THR 1, ASN 2, GLY 0LYS 3
HADQLTPTWR0.507.100.521224.34Good0.36330%6/60.004/40.00GLN 1, HIS 1, THR 2, GLY 0ARG 1, ASP 1
YQTQTNSPRR2.0010.840.741250.34Good-0.0900%8/80.002/20.00GLN 2, SER 1, THR 2, ASN 1, GLY 0ARG 2
TQTNSPRRAR3.0012.310.861186.30Good-0.23410%8/80.002/20.00GLN 1, SER 1, THR 2, ASN 1, GLY 0ARG 3
TNSPRRARSV3.0012.310.741143.27Good-0.12020%7/70.003/30.00SER 2, THR 1, ASN 1, GLY 0ARG 3
NSPRRARSVA3.0012.310.741113.25Good-0.11530%6/60.004/40.00SER 2, ASN 1, GLY 0ARG 3
PRRARSVASQ3.0012.310.861127.27Good-0.07730%6/60.004/40.00GLN 1, SER 2, GLY 0ARG 3
KQIYKTPPIK3.0010.011.231215.50Good0.30720%5/50.005/50.00GLN 1, THR 1, GLY 0LYS 3
SQILPDPSKP0.006.190.491081.23Good0.36020%5/50.005/50.00GLN 1, SER 2, GLY 0LYS 1, ASP 1
RLITGRLQSL2.0012.010.611156.39Good0.48840%6/60.004/40.00GLN 1, SER 1, THR 1, GLY 1ARG 2
M protein
NRNRFLYIIK3.0011.010.861336.60Good0.38440%5/50.005/50.00ASN 2, GLY 0LYS 1, ARG 2
RNRFLYIIKL3.0011.010.861335.66Good0.61450%4/40.006/60.00ASN 1, GLY 0LYS 1, ARG 2
YIIKLIFLWL1.008.940.371321.71Poor1.45180%1/10.009/90.00GLY 0LYS 1
KLIFLWLLWP1.009.110.371328.71Poor1.46280%1/10.009/90.00GLY 0LYS 1
FIASFRLFAR2.0012.010.491227.48Poor0.74370%3/30.007/70.00SER 1, GLY 0ARG 2
ASFRLFARTR3.0012.310.741224.43Good0.30950%5/50.005/50.00SER 1, THR 1, GLY 0ARG 3
SFRLFARTRS3.0012.310.741240.43Good0.27440%6/60.004/40.00SER 2, THR 1, GLY 0ARG 3
FRLFARTRSM3.0012.310.741284.55Good0.40150%5/50.005/50.00SER 1, THR 1, GLY 0ARG 3
RLFARTRSMW3.0012.310.741323.59Good0.44750%5/50.005/50.00SER 1, THR 1, GLY 0ARG 3
FARTRSMWSF2.0012.010.491323.59Poor0.55350%5/50.005/50.00SER 2, THR 1, GLY 0ARG 2
HGTILTRPLL1.5010.110.391120.36Poor0.72640%5/50.005/50.00HIS 1, THR 2, GLY 1ARG 1
GAVILRGHLR2.5012.010.641091.33Good0.48450%5/50.005/50.00HIS 1, GLY 2ARG 2
RIAGHHLGRC3.0010.380.781119.32Good0.35940%6/60.004/40.00HIS 2, GLY 2ARG 2
YSRYRIGNYK3.0010.000.861319.49Good0.10310%6/60.004/40.00SER 1, ASN 1, GLY 1LYS 1, ARG 2
N protein
PQNQRNAPRI2.0012.010.741193.33Good-0.01120%6/60.004/40.00GLN 2, ASN 2, GLY 0ARG 2
ERSGARSKQR3.0011.721.351174.29Good-0.46510%9/90.001/10.00GLN 1, SER 2, GLY 1LYS 1, ARG 3, GLU 1
RSGARSKQRR5.0012.481.471201.36Good-0.50210%9/90.001/10.00GLN 1, SER 2, GLY 1LYS 1, ARG 4
SGARSKQRRP4.0012.311.231142.29Good-0.32910%8/80.002/20.00GLN 1, SER 2, GLY 1LYS 1, ARG 3
GARSKQRRPQ4.0012.311.351183.34Good-0.34710%8/80.002/20.00GLN 2, SER 1, GLY 1LYS 1, ARG 3
ARSKQRRPQG4.0012.311.351183.34Good-0.34710%8/80.002/20.00GLN 2, SER 1, GLY 1LYS 1, ARG 3
RSKQRRPQGL4.0012.311.351225.42Good-0.20810%8/80.002/20.00GLN 2, SER 1, GLY 1LYS 1, ARG 3
SKQRRPQGLP3.0012.011.111166.35Good-0.03510%7/70.003/30.00GLN 2, SER 1, GLY 1LYS 1, ARG 2
KQRRPQGLPN3.0012.011.111193.38Good-0.09110%7/70.003/30.00GLN 2, ASN 1, GLY 1LYS 1, ARG 2
RRPQGLPNNT2.0012.010.611152.28Good-0.00410%7/70.003/30.00GLN 1, THR 1, ASN 2, GLY 1ARG 2
QIGYYRRATR3.0010.910.861283.46Good0.10420%6/60.004/40.00GLN 1, THR 1, GLY 1ARG 3
IGYYRRATRR4.0011.560.981311.51Good0.02520%6/60.004/40.00THR 1, GLY 1ARG 4
GYYRRATRRI4.0011.560.981311.51Good0.02520%6/60.004/40.00THR 1, GLY 1ARG 4
YYRRATRRIR5.0011.841.231410.65Good-0.07620%6/60.004/40.00THR 1, GLY 0ARG 5
YRRATRRIRG5.0012.181.231410.65Good-0.17220%7/70.003/30.00THR 1, GLY 1ARG 5
RRATRRIRGG5.0012.611.231198.40Good-0.26820%8/80.002/20.00THR 1, GLY 2ARG 5
RATRRIRGGD3.0012.010.981157.30Good-0.24420%8/80.002/20.00THR 1, GLY 2ARG 4, ASP 1
TRRIRGGDGK3.0011.721.101115.26Good-0.27330%9/90.001/10.00THR 1, GLY 3LYS 1, ARG 3, ASP 1
RIRGGDGKMK3.0011.011.221117.34Good-0.17420%8/80.002/20.00GLY 3LYS 2, ARG 2, ASP 1
GKMKDLSPRW2.0010.010.981217.46Good0.21030%6/60.004/40.00SER 1, GLY 1LYS 2, ARG 1, ASP 1
SQASSRSSSR2.0012.010.611052.07Good-0.21710%9/90.001/10.00GLN 1, SER 6, GLY 0ARG 2
ASSRSSSRSR3.0012.310.741080.13Good-0.29610%9/90.001/10.00SER 6, GLY 0ARG 3
SSRSSSRSRN3.0012.310.741123.15Good-0.3870%10/100.000/0.00SER 6, ASN 1, GLY 0ARG 3
SRSSSRSRNS3.0012.310.741123.15Good-0.3870%10/100.000/0.00SER 6, ASN 1, GLY 0ARG 3
RSSSRSRNSS3.0012.310.741123.15Good-0.3870%10/100.000/0.00SER 6, ASN 1, GLY 0ARG 3
SSSRSRNSSR3.0012.310.741123.15Good-0.3870%10/100.000/0.00SER 6, ASN 1, GLY 0ARG 3
SSRSRNSSRN3.0012.310.741150.18Good-0.4430%10/100.000/0.00SER 5, ASN 2, GLY 0ARG 3
RSRNSSRNST3.0012.310.741164.20Good-0.4130%10/100.000/0.00SER 4, THR 1, ASN 2, GLY 0ARG 3
GSSRGTSPAR2.0012.010.49975.03Good-0.08510%8/80.002/20.00SER 3, THR 1, GLY 2ARG 2
AALALLLLDR0.006.190.251068.33Poor0.76580%2/20.008/80.00GLY 0ARG 1, ASP 1
ALALLLLDRL0.006.190.251110.41Poor0.90480%2/20.008/80.00GLY 0ARG 1, ASP 1
KKSAAEASKK3.0010.011.591047.22Good-0.37530%7/70.003/30.00SER 2, GLY 0LYS 4, GLU 1
KSAAEASKKP2.009.721.231016.16Good-0.20430%6/60.004/40.00SER 2, GLY 0LYS 3, GLU 1
SAAEASKKPR2.0010.011.111044.18Good-0.20630%6/60.004/40.00SER 2, GLY 0LYS 2, ARG 1, GLU 1
AAEASKKPRQ2.0010.011.231085.23Good-0.22430%6/60.004/40.00GLN 1, SER 1, GLY 0LYS 2, ARG 1, GLU 1
AEASKKPRQK3.0010.301.601142.32Good-0.35420%7/70.003/30.00GLN 1, SER 1, GLY 0LYS 3, ARG 1, GLU 1
EASKKPRQKR4.0011.101.841227.43Good-0.48610%8/80.002/20.00GLN 1, SER 1, GLY 0LYS 3, ARG 2, GLU 1
ASKKPRQKRT5.0012.031.721199.42Good-0.39610%8/80.002/20.00GLN 1, SER 1, THR 1, GLY 0LYS 3, ARG 2
SKKPRQKRTA5.0012.031.721199.42Good-0.39610%8/80.002/20.00GLN 1, SER 1, THR 1, GLY 0LYS 3, ARG 2
KKPRQKRTAT5.0012.031.721213.45Good-0.36610%8/80.002/20.00GLN 1, THR 2, GLY 0LYS 3, ARG 2
KPRQKRTATK5.0012.031.721213.45Good-0.36610%8/80.002/20.00GLN 1, THR 2, GLY 0LYS 3, ARG 2
PRQKRTATKA4.0012.021.351156.35Good-0.23620%7/70.003/30.00GLN 1, THR 2, GLY 0LYS 2, ARG 2
RQKRTATKAY4.0011.101.351222.41Good-0.21220%7/70.003/30.00GLN 1, THR 2, GLY 0LYS 2, ARG 2
RQGTDYKHWP1.508.940.881287.40Good0.13310%7/70.003/30.00GLN 1, HIS 1, THR 1, GLY 1LYS 1, ARG 1, ASP 1
FPPTEPKKDK1.008.831.231186.37Good-0.01710%6/60.004/40.00THR 1, GLY 0LYS 3, GLU 1, ASP 1
PPTEPKKDKK2.009.551.591167.37Good-0.2950%7/70.003/30.00THR 1, GLY 0LYS 4, GLU 1, ASP 1
PTEPKKDKKK3.009.841.961198.43Good-0.4660%8/80.002/20.00THR 1, GLY 0LYS 5, GLU 1, ASP 1
TEPKKDKKKK4.0010.012.331229.49Good-0.6370%9/90.001/10.00THR 1, GLY 0LYS 6, GLU 1, ASP 1
EPKKDKKKKA4.0010.012.331199.46Good-0.63210%8/80.002/20.00GLY 0LYS 6, GLU 1, ASP 1
PKKDKKKKAD4.0010.012.201185.43Good-0.64510%8/80.002/20.00GLY 0LYS 6, ASP 2
KKDKKKKADE3.009.712.331217.43Good-0.78110%9/90.001/10.00GLY 0LYS 6, GLU 1, ASP 2
TQALPQRQKK3.0011.171.351197.40Good-0.06620%7/70.003/30.00GLN 3, THR 1, GLY 0LYS 2, ARG 1
ALPQRQKKQQ3.0011.171.481224.43Good-0.11420%7/70.003/30.00GLN 4, GLY 0LYS 2, ARG 1
ORF3a
SASKIITLKK3.0010.311.101088.36Good0.28240%6/60.004/40.00SER 2, THR 1, GLY 0LYS 3
ASKIITLKKR4.0011.271.351157.47Good0.18540%6/60.004/40.00SER 1, THR 1, GLY 0LYS 3, ARG 1
SKIITLKKRW4.0011.271.351272.60Good0.37940%6/60.004/40.00SER 1, THR 1, GLY 0LYS 3, ARG 1
KIITLKKRWQ4.0011.271.471313.65Good0.36140%6/60.004/40.00GLN 1, THR 1, GLY 0LYS 3, ARG 1
IITLKKRWQL3.0011.171.101298.64Good0.63050%5/50.005/50.00GLN 1, THR 1, GLY 0LYS 2, ARG 1
KKRWQLALSK4.0011.271.471257.55Good0.17240%6/60.004/40.00GLN 1, SER 1, GLY 0LYS 3, ARG 1
KRWQLALSKG3.0011.171.101186.42Good0.27140%6/60.004/40.00GLN 1, SER 1, GLY 1LYS 2, ARG 1
VRIIMRLWLC2.0010.380.491302.72Poor1.12280%2/20.008/80.00GLY 0ARG 2
RIIMRLWLCW2.0010.380.491389.80Poor1.22580%2/20.008/80.00GLY 0ARG 2
IIMRLWLCWK2.009.550.611361.79Poor1.22780%2/20.008/80.00GLY 0LYS 1, ARG 1
IMRLWLCWKC2.009.030.611351.77Poor1.20180%2/20.008/80.00GLY 0LYS 1, ARG 1
MRLWLCWKCR3.009.720.861394.80Good0.92070%3/30.007/70.00GLY 0LYS 1, ARG 2
RLWLCWKCRS3.009.720.861350.68Good0.79360%4/40.006/60.00SER 1, GLY 0LYS 1, ARG 2
LWLCWKCRSK3.009.530.981322.66Good0.79560%4/40.006/60.00SER 1, GLY 0LYS 2, ARG 1
WLCWKCRSKN3.009.530.981323.61Good0.56550%5/50.005/50.00SER 1, ASN 1, GLY 0LYS 2, ARG 1
LCWKCRSKNP3.009.530.981234.51Good0.41240%5/50.005/50.00SER 1, ASN 1, GLY 0LYS 2, ARG 1
CWKCRSKNPL3.009.530.981234.51Good0.41240%5/50.005/50.00SER 1, ASN 1, GLY 0LYS 2, ARG 1
KCRSKNPLLY3.009.800.981221.49Good0.29930%5/50.005/50.00SER 1, ASN 1, GLY 0LYS 2, ARG 1
Orf1ab
IKRSDARTAP2.0010.840.861114.27Good-0.04230%6/60.004/40.00SER 1, THR 1, GLY 0LYS 1, ARG 2, ASP 1
KRSDARTAPH2.5010.841.001138.25Good-0.20920%7/70.003/30.00HIS 1, SER 1, THR 1, GLY 0LYS 1, ARG 2, ASP 1
PVAYRKVLLR3.0011.010.861214.52Good0.48250%3/30.007/70.00GLY 0LYS 1, ARG 2
VAYRKVLLRK4.0011.101.221245.58Good0.31150%4/40.006/60.00GLY 0LYS 2, ARG 2
AYRKVLLRKN4.0011.101.221260.55Good0.12940%5/50.005/50.00ASN 1, GLY 0LYS 2, ARG 2
YRKVLLRKNG4.0011.101.221246.52Good0.09830%6/60.004/40.00ASN 1, GLY 1LYS 2, ARG 2
RKVLLRKNGN4.0012.021.221197.45Good-0.05830%7/70.003/30.00ASN 2, GLY 1LYS 2, ARG 2
KVLLRKNGNK4.0011.271.351169.44Good-0.05630%7/70.003/30.00ASN 2, GLY 1LYS 3, ARG 1
FEIKLAKKFD1.008.831.231238.49Good0.30150%5/50.005/50.00GLY 0LYS 3, GLU 1, ASP 1
KTIQPRVEKK3.0010.301.601226.49Good-0.08420%7/70.003/30.00GLN 1, THR 1, GLY 0LYS 3, ARG 1, GLU 1
TIQPRVEKKK3.0010.301.601226.49Good-0.08420%7/70.003/30.00GLN 1, THR 1, GLY 0LYS 3, ARG 1, GLU 1
IQPRVEKKKL3.0010.301.601238.54Good0.06030%6/60.004/40.00GLN 1, GLY 0LYS 3, ARG 1, GLU 1
SGLKTILRKG3.0011.170.981072.32Good0.24330%7/70.003/30.00SER 1, THR 1, GLY 2LYS 2, ARG 1
LKTILRKGGR4.0012.021.221141.43Good0.14630%7/70.003/30.00THR 1, GLY 2LYS 2, ARG 2
KTILRKGGRT4.0012.021.221129.37Good0.00220%8/80.002/20.00THR 2, GLY 2LYS 2, ARG 2
GNFKVTKGKA3.0010.311.101049.24Good0.00130%7/70.003/30.00THR 1, ASN 1, GLY 2LYS 3
FKVTKGKAKK5.0010.611.841134.43Good-0.13730%7/70.003/30.00THR 1, GLY 1LYS 5
KVTKGKAKKG5.0010.611.841044.31Good-0.31620%8/80.002/20.00THR 1, GLY 2LYS 5
KGKAKKGAWN4.0010.491.471087.29Good-0.16930%7/70.003/30.00ASN 1, GLY 2LYS 4
GGAKLKALNL2.0010.020.73984.21Good0.31450%5/50.005/50.00ASN 1, GLY 2LYS 2
SKGLYRKCVK4.0010.041.351181.47Good0.14030%6/60.004/40.00SER 1, GLY 1LYS 3, ARG 1
KGLYRKCVKS4.0010.041.351181.47Good0.14030%6/60.004/40.00SER 1, GLY 1LYS 3, ARG 1
GLYRKCVKSR4.0010.321.221209.48Good0.13830%6/60.004/40.00SER 1, GLY 1LYS 2, ARG 2
GLLMPLKAPK2.0010.020.731067.40Good0.61050%3/30.007/70.00GLY 1LYS 2
QRKQDDKKIK3.0010.011.961286.50Good-0.51510%9/90.001/10.00GLN 2, GLY 0LYS 4, ARG 1, ASP 2
RKQDDKKIKA3.0010.011.841229.45Good-0.46220%8/80.002/20.00GLN 1, GLY 0LYS 4, ARG 1, ASP 2
KQDDKKIKAC2.009.171.591176.40Good-0.20730%7/70.003/30.00GLN 1, GLY 0LYS 4, ASP 2
DITFLKKDAP0.006.310.731147.34Good0.30640%5/50.005/50.00THR 1, GLY 0LYS 2, ASP 2
MLAKALRKVP3.0011.170.981126.48Good0.42060%3/30.007/70.00GLY 0LYS 2, ARG 1
LAKALRKVPT3.0011.170.981096.38Good0.32350%4/40.006/60.00THR 1, GLY 0LYS 2, ARG 1
EAKTVLKKCK3.009.651.591147.45Good0.04340%6/60.004/40.00THR 1, GLY 0LYS 4, GLU 1
AKTVLKKCKS4.0010.051.471105.41Good0.10340%6/60.004/40.00SER 1, THR 1, GLY 0LYS 4
KTVLKKCKSA4.0010.051.471105.41Good0.10340%6/60.004/40.00SER 1, THR 1, GLY 0LYS 4
KSAFYILPSI1.008.940.371138.37Poor0.80150%3/30.007/70.00SER 2, GLY 0LYS 1
KAIVSTIQRK3.0011.171.101143.40Good0.21440%6/60.004/40.00GLN 1, SER 1, THR 1, GLY 0LYS 2, ARG 1
STIQRKYKGI3.0010.301.101193.41Good0.15720%7/70.003/30.00GLN 1, SER 1, THR 1, GLY 1LYS 2, ARG 1
TIQRKYKGIK4.0010.471.471234.5Good0.06220%7/70.003/30.00GLN 1, THR 1, GLY 1LYS 3, ARG 1
IQRKYKGIKI4.0010.471.471246.56Good0.21630%6/60.004/40.00GLN 1, GLY 1LYS 3, ARG 1
GARFYFYTSK2.009.720.611239.40Poor0.40330%5/50.005/50.00SER 1, THR 1, GLY 1LYS 1, ARG 1
ARYMRSLKVP3.0011.010.861220.51Good0.30940%4/40.006/60.00SER 1, GLY 0LYS 1, ARG 2
GIEFLKRGDK1.008.931.111162.35Good0.08930%7/70.003/30.00GLY 2LYS 2, ARG 1, GLU 1, ASP 1
DNLKTLLSLR1.009.100.611172.39Good0.36540%6/60.004/40.00SER 1, THR 1, ASN 1, GLY 0LYS 1, ARG 1, ASP 1
YMSALNHTKK2.509.720.881192.41Good0.19730%6/60.004/40.00HIS 1, SER 1, THR 1, ASN 1, GLY 0LYS 2
SALNHTKKWK3.5010.311.251212.42Good0.10430%7/70.003/30.00HIS 1, SER 1, THR 1, ASN 1, GLY 0LYS 3
ALNHTKKWKY3.5010.011.251288.52Good0.20430%6/60.004/40.00HIS 1, THR 1, ASN 1, GLY 0LYS 3
LNHTKKWKYP3.5010.011.251314.55Good0.24520%6/60.004/40.00HIS 1, THR 1, ASN 1, GLY 0LYS 3
NHTKKWKYPQ3.5010.011.371329.52Good0.05310%7/70.003/30.00GLN 1, HIS 1, THR 1, ASN 1, GLY 0LYS 3
HTKKWKYPQV3.5010.011.371314.55Good0.23520%6/60.004/40.00GLN 1, HIS 1, THR 1, GLY 0LYS 3
KKPASRELKV3.0010.301.471155.41Good-0.07130%6/60.004/40.00SER 1, GLY 0LYS 3, ARG 1, GLU 1
KPASRELKVT2.0010.011.111128.34Good0.05430%6/60.004/40.00SER 1, THR 1, GLY 0LYS 2, ARG 1, GLU 1
YTPSFKKGAK3.0010.011.101126.32Good0.10320%6/60.004/40.00SER 1, THR 1, GLY 1LYS 3
PSFKKGAKLL3.0010.311.101088.36Good0.32140%5/50.005/50.00SER 1, GLY 1LYS 3
FKKGAKLLHK4.5010.491.611169.48Good0.16740%6/60.004/40.00HIS 1, GLY 1LYS 4
KKGAKLLHKP4.5010.491.611119.42Good0.06030%6/60.004/40.00HIS 1, GLY 1LYS 4
KGAKLLHKPI3.5010.311.251104.41Good0.33940%5/50.005/50.00HIS 1, GLY 1LYS 3
WCIRCLWSTK2.009.030.611295.60Poor0.93060%4/40.006/60.00SER 1, THR 1, GLY 0LYS 1, ARG 1
CIRCLWSTKP2.009.030.611206.50Poor0.77750%4/40.006/60.00SER 1, THR 1, GLY 0LYS 1, ARG 1
ANYAKPFLNK2.009.70.731165.36Good0.26133%4/40.006/60.00ASN 2, GLY 0LYS 2
TNIVTRCLNR2.0010.380.491189.40Good0.35640%6/60.004/40.00THR 2, ASN 2, GLY 0ARG 2
CTFTRSTNSR2.0010.380.491172.29Good0.14120%8/80.002/20.00SER 2, THR 3, ASN 1, GLY 0ARG 2
TCMMCYKRNR3.009.530.861305.64Good0.31540%5/50.005/50.00THR 1, ASN 1, GLY 0LYS 1, ARG 2
MCYKRNRATR4.0010.921.101298.56Good-0.03230%6/60.004/40.00THR 1, ASN 1, GLY 0LYS 1, ARG 3
CYKRNRATRV4.0010.921.101266.49Good-0.03330%6/60.004/40.00THR 1, ASN 1, GLY 0LYS 1, ARG 3
YKRNRATRVE3.0010.911.231292.46Good-0.25120%7/70.003/30.00THR 1, ASN 1, GLY 0LYS 1, ARG 3, GLU 1
KRNRATRVEC3.0010.771.231232.43Good-0.19330%7/70.003/30.00THR 1, ASN 1, GLY 0LYS 1, ARG 3, GLU 1
RNRATRVECT2.0010.290.861205.36Good-0.06830%7/70.003/30.00THR 2, ASN 1, GLY 0ARG 3, GLU 1
RDLSLQFKRP2.0010.840.981259.47Good0.18730%6/60.004/40.00GLN 1, SER 1, GLY 0LYS 1, ARG 2, ASP 1
SLQFKRPINP2.0011.010.741199.42Good0.38730%5/50.005/50.00GLN 1, SER 1, ASN 1, GLY 0LYS 1, ARG 1
HNIALIWNVK1.509.110.511207.44Poor0.70260%4/40.006/60.00HIS 1, ASN 2, GLY 0LYS 1
LSEQLRKQIR2.0010.841.231270.50Good0.10730%7/70.003/30.00GLN 2, SER 1, GLY 0LYS 1, ARG 2, GLU 1
QLRKQIRSAA3.0012.011.111170.38Good0.06340%6/60.004/40.00GLN 2, SER 1, GLY 0LYS 1, ARG 2
LRKQIRSAAK4.0012.021.351170.42Good-0.01440%6/60.004/40.00GLN 1, SER 1, GLY 0LYS 2, ARG 2
RKQIRSAAKK5.0012.031.721185.44Good-0.28330%7/70.003/30.00GLN 1, SER 1, GLY 0LYS 3, ARG 2
KQIRSAAKKN4.0011.271.471143.36Good-0.24230%7/70.003/30.00GLN 1, SER 1, ASN 1, GLY 0LYS 3, ARG 1
QIRSAAKKNN3.0011.171.101129.29Good-0.20330%7/70.003/30.00GLN 1, SER 1, ASN 2, GLY 0LYS 2, ARG 1
AAKKNNLPFK3.0010.311.101130.36Good0.06640%5/50.005/50.00ASN 2, GLY 0LYS 3
KKNNLPFKLT3.0010.311.101202.46Good0.20030%6/60.004/40.00THR 1, ASN 2, GLY 0LYS 3
NNWLKQLIKV2.0010.020.861255.53Poor0.52750%5/50.005/50.00GLN 1, ASN 2, GLY 0LYS 2
LAYYFMRFRR3.0010.910.741422.72Good0.57150%3/30.007/70.00GLY 0ARG 3
AYYFMRFRRA3.0010.910.741380.64Good0.43250%3/30.007/70.00GLY 0ARG 3
YYFMRFRRAF3.0010.910.741456.74Poor0.58050%3/30.007/70.00GLY 0ARG 3
FMRFRRAFGE2.0011.700.861316.55Good0.32450%5/50.005/50.00GLY 1ARG 3, GLU 1
MRFRRAFGEY2.0010.750.861332.55Good0.24140%5/50.005/50.00GLY 1ARG 3, GLU 1
KEMYLKLRSD1.008.831.111282.53Good0.11530%6/60.004/40.00SER 1, GLY 0LYS 2, ARG 1, GLU 1, ASP 1
YNRYLALYNK2.009.550.611317.51Poor0.33930%4/40.006/60.00ASN 2, GLY 0LYS 1, ARG 1
RYLALYNKYK3.009.830.981331.58Good0.30030%4/40.006/60.00ASN 1, GLY 0LYS 2, ARG 1
FRKMAFPSGK3.0011.170.981168.43Good0.28140%5/50.005/50.00SER 1, GLY 1LYS 2, ARG 1
TANPKTPKYK3.0010.011.101147.34Good-0.03410%6/60.004/40.00THR 2, ASN 1, GLY 0LYS 3
ANPKTPKYKF3.0010.011.101193.41Good0.11920%5/50.005/50.00THR 1, ASN 1, GLY 0LYS 3
PKTPKYKFVR4.0010.471.351263.55Good0.16920%5/50.005/50.00THR 1, GLY 0LYS 3, ARG 1
KTPKYKFVRI4.0010.471.351279.59Good0.27730%5/50.005/50.00THR 1, GLY 0LYS 3, ARG 1
RWFLNRFTTT2.0012.010.491341.54Poor0.56940%6/60.004/40.00THR 3, ASN 1, GLY 0ARG 2
FQSAVKRTIK3.0011.171.101177.41Good0.21340%6/60.004/40.00GLN 1, SER 1, THR 1, GLY 0LYS 2, ARG 1
SEVVLKKLKK3.0010.011.591171.49Good0.12040%6/60.004/40.00SER 1, GLY 0LYS 4, GLU 1
VVLKKLKKSL4.0010.491.471155.53Good0.35450%5/50.005/50.00SER 1, GLY 0LYS 4
VLKKLKKSLN4.0010.491.471170.51Good0.17240%6/60.004/40.00SER 1, ASN 1, GLY 0LYS 4
KKLKKSLNVA4.0010.491.471128.42Good0.03340%6/60.004/40.00SER 1, ASN 1, GLY 0LYS 4
DAAMQRKLEK1.008.931.231189.40Good-0.10740%6/60.004/40.00GLN 1, GLY 0LYS 2, ARG 1, GLU 1, ASP 1
AAMQRKLEKM2.0010.011.231205.51Good0.09350%5/50.005/50.00GLN 1, GLY 0LYS 2, ARG 1, GLU 1
MQRKLEKMAD1.008.931.231249.52Good-0.01540%6/60.004/40.00GLN 1, GLY 0LYS 2, ARG 1, GLU 1, ASP 1
YKQARSEDKR2.009.721.481280.41Good-0.44010%8/80.002/20.00GLN 1, SER 1, GLY 0LYS 2, ARG 2, GLU 1, ASP 1
KQARSEDKRA2.0010.001.481188.31Good-0.50520%8/80.002/20.00GLN 1, SER 1, GLY 0LYS 2, ARG 2, GLU 1, ASP 1
QARSEDKRAK2.0010.001.481188.31Good-0.50520%8/80.002/20.00GLN 1, SER 1, GLY 0LYS 2, ARG 2, GLU 1, ASP 1
MLFTMLRKLD1.009.100.611267.62Good0.68460%4/40.006/60.00THR 1, GLY 0LYS 1, ARG 1, ASP 1
QDLKWARFPK2.0010.011.101288.52Good0.27940%5/50.005/50.00GLN 1, GLY 0LYS 2, ARG 1, ASP 1
DLKWARFPKS2.0010.010.981247.46Good0.29740%5/50.005/50.00SER 1, GLY 0LYS 2, ARG 1, ASP 1
LKWARFPKSD2.0010.010.981247.46Good0.29740%5/50.005/50.00SER 1, GLY 0LYS 2, ARG 1, ASP 1
KGFCDLKGKY2.009.171.101158.39Good0.22530%6/60.004/40.00GLY 2LYS 3, ASP 1
GVSAARLTPC1.008.600.25974.15Poor0.50150%4/40.006/60.00SER 1, THR 1, GLY 1ARG 1
GFAKFLKTNC2.009.360.731128.36Poor0.48150%5/50.005/50.00THR 1, ASN 1, GLY 1LYS 2
KTNCCRFQEK2.008.981.231256.47Good0.06830%7/70.003/30.00GLN 1, THR 1, ASN 1, GLY 0LYS 2, ARG 1, GLU 1
PHISRQRLTK3.5012.011.131235.46Good0.13420%7/70.003/30.00GLN 1, HIS 1, SER 1, THR 1, GLY 0LYS 1, ARG 2
HISRQRLTKY3.5011.011.131301.52Good0.15820%7/70.003/30.00GLN 1, HIS 1, SER 1, THR 1, GLY 0LYS 1, ARG 2
ISRQRLTKYT3.0011.010.981265.48Good0.17120%7/70.003/30.00GLN 1, SER 1, THR 2, GLY 0LYS 1, ARG 2
SRQRLTKYTM3.0011.010.981283.52Good0.11420%7/70.003/30.00GLN 1, SER 1, THR 2, GLY 0LYS 1, ARG 2
RQRLTKYTMA3.0011.010.981267.52Good0.14930%6/60.004/40.00GLN 1, THR 2, GLY 0LYS 1, ARG 2
GERVRQALLK2.0010.841.111169.39Good0.10640%6/60.004/40.00GLN 1, GLY 1LYS 1, ARG 2, GLU 1
RVRQALLKTV3.0012.010.981183.46Good0.31850%5/50.005/50.00GLN 1, THR 1, GLY 0LYS 1, ARG 2
KPYIKWDLLK2.009.551.101303.61Good0.53940%4/40.006/60.00GLY 0LYS 3, ASP 1
RLKLFDRYFK3.0010.291.221385.68Good0.31740%5/50.005/50.00GLY 0LYS 2, ARG 2, ASP 1
KLFDRYFKYW2.009.550.981465.72Good0.56940%4/40.006/60.00GLY 0LYS 2, ARG 1, ASP 1
FPFNKWGKAR3.0011.170.981250.47Good0.32740%5/50.005/50.00ASN 1, GLY 1LYS 2, ARG 1
KWGKARLYYD2.009.550.981299.50Good0.24230%5/50.005/50.00GLY 1LYS 2, ARG 1, ASP 1
YAISAKNRAR3.0011.010.861149.32Good0.00440%5/50.005/50.00SER 1, ASN 1, GLY 0LYS 1, ARG 2
AISAKNRART3.0012.010.861087.25Good-0.06640%6/60.004/40.00SER 1, THR 1, ASN 1, GLY 0LYS 1, ARG 2
KNRARTVAGV3.0012.010.861071.25Good-0.02940%6/60.004/40.00THR 1, ASN 1, GLY 1LYS 1, ARG 2
NRQFHQKLLK3.5011.171.371311.55Good0.12930%7/70.003/30.00GLN 2, HIS 1, ASN 1, GLY 0LYS 2, ARG 1
RQFHQKLLKS3.5011.171.371284.53Good0.18530%7/70.003/30.00GLN 2, HIS 1, SER 1, GLY 0LYS 2, ARG 1
RIMASLVLAR2.0012.010.491129.44Poor0.62170%3/30.007/70.00SER 1, GLY 0ARG 2
RNLQHRLYEC1.508.570.891331.52Good0.25530%6/60.004/40.00GLN 1, HIS 1, ASN 1, GLY 0ARG 2, GLU 1
RLYECLYRNR2.009.360.861385.61Good0.25930%5/50.005/50.00ASN 1, GLY 0ARG 3, GLU 1
SLRCGACIRR3.0010.430.741134.40Good0.38250%5/50.005/50.00SER 1, GLY 1ARG 3
RCGACIRRPF3.0010.430.741178.45Good0.46750%4/40.006/60.00GLY 1ARG 3
CGACIRRPFL2.009.100.491135.42Poor0.73860%3/30.007/70.00GLY 1ARG 2
GACIRRPFLC2.009.100.491135.42Poor0.73860%3/30.007/70.00GLY 1ARG 2
ACIRRPFLCC2.008.820.491181.52Poor0.89270%2/20.008/80.00GLY 0ARG 2
CIRRPFLCCK3.009.260.861238.61Good0.76260%3/30.007/70.00GLY 0LYS 1, ARG 2
IRRPFLCCKC3.009.260.861238.61Good0.76260%3/30.007/70.00GLY 0LYS 1, ARG 2
RRPFLCCKCC3.009.020.861228.60Good0.73660%3/30.007/70.00GLY 0LYS 1, ARG 2
MSYYCKSHKP2.509.170.881243.47Good0.34820%5/50.005/50.00HIS 1, SER 2, GLY 0LYS 2
ANTCTERLKL1.008.570.741148.35Good0.25340%6/60.004/40.00THR 2, ASN 1, GLY 0LYS 1, ARG 1, GLU 1
SWEVGKPRPP1.009.100.741152.32Good0.29520%5/50.005/50.00SER 1, GLY 1LYS 1, ARG 1, GLU 1
VGKPRPPLNR3.0012.010.861133.36Good0.14720%5/50.005/50.00ASN 1, GLY 1LYS 1, ARG 2
GKPRPPLNRN3.0012.010.861148.33Good-0.03510%6/60.004/40.00ASN 2, GLY 1LYS 1, ARG 2
KALKYLPIDK2.009.551.101188.48Good0.34540%4/40.006/60.00GLY 0LYS 3, ASP 1
DKCSRIIPAR2.009.550.861158.39Good0.23540%5/50.005/50.00SER 1, GLY 0LYS 1, ARG 2, ASP 1
KCSRIIPARA3.0010.870.861114.38Good0.34350%4/40.006/60.00SER 1, GLY 0LYS 1, ARG 2
CSRIIPARAR3.0011.710.741142.39Good0.34150%4/40.006/60.00SER 1, GLY 0ARG 3
SRIIPARARV3.0012.310.741138.38Good0.30950%4/40.006/60.00SER 1, GLY 0ARG 3
RIIPARARVE2.0011.700.861180.42Good0.24950%4/40.006/60.00GLY 0ARG 3, GLU 1
SVVNARLRAK3.0012.010.861113.33Good0.11150%5/50.005/50.00SER 1, ASN 1, GLY 0LYS 1, ARG 2
VVNARLRAKH3.5012.011.001163.39Good0.12850%5/50.005/50.00HIS 1, ASN 1, GLY 0LYS 1, ARG 2
VNARLRAKHY3.5011.011.001227.44Good0.10240%5/50.005/50.00HIS 1, ASN 1, GLY 0LYS 1, ARG 2
NARLRAKHYV3.5011.011.001227.44Good0.10240%5/50.005/50.00HIS 1, ASN 1, GLY 0LYS 1, ARG 2
PAPRTLLTKG2.0011.010.611053.27Good0.36730%5/50.005/50.00THR 2, GLY 1LYS 1, ARG 1
APRTLLTKGT2.0011.010.611057.26Good0.32130%6/60.004/40.00THR 3, GLY 1LYS 1, ARG 1
FNSVCRLMKT2.009.550.611198.48Good0.51050%5/50.005/50.00SER 1, THR 1, ASN 1, GLY 0LYS 1, ARG 1
FLGTCRRCPA2.009.100.491123.37Good0.58450%4/40.006/60.00THR 1, GLY 1ARG 2
DNKLKAHKDK2.509.551.611196.37Good-0.39620%8/80.002/20.00HIS 1, ASN 1, GLY 0LYS 4, ASP 2
KLKAHKDKSA3.5010.011.611125.34Good-0.23230%7/70.003/30.00HIS 1, SER 1, GLY 0LYS 4, ASP 1
FLTRNPAWRK3.0012.010.861288.52Good0.34240%5/50.005/50.00THR 1, ASN 1, GLY 0LYS 1, ARG 2
RNPAWRKAVF3.0012.010.861244.47Good0.29950%4/40.006/60.00ASN 1, GLY 0LYS 1, ARG 2
GIPKDMTYRR2.0010.000.861236.46Good0.11920%6/60.004/40.00THR 1, GLY 1LYS 1, ARG 2, ASP 1
DMTYRRLISM1.009.100.491285.55Good0.43540%5/50.005/50.00SER 1, THR 1, GLY 0ARG 2, ASP 1
GNPKAIKCVP2.009.360.731026.27Good0.37340%4/40.006/60.00ASN 1, GLY 1LYS 2
WNTFTRLQSL1.0010.110.371265.43Poor0.60940%6/60.004/40.00GLN 1, SER 1, THR 2, ASN 1, GLY 0ARG 1
ELWAKRNIKP2.0010.011.111254.50Good0.25540%5/50.005/50.00ASN 1, GLY 0LYS 2, ARG 1, GLU 1
LWAKRNIKPV3.0011.170.981224.52Good0.44150%4/40.006/60.00ASN 1, GLY 0LYS 2, ARG 1
WAKRNIKPVP3.0011.170.981208.47Good0.34340%4/40.006/60.00ASN 1, GLY 0LYS 2, ARG 1
RNIKPVPEVK2.0010.011.111179.43Good0.14530%5/50.005/50.00ASN 1, GLY 0LYS 2, ARG 1, GLU 1
LLIGLAKRFK3.0011.170.981158.50Good0.60160%4/40.006/60.00GLY 1LYS 2, ARG 1
GLAKRFKESP2.0010.011.111132.33Good0.08530%6/60.004/40.00SER 1, GLY 1LYS 2, ARG 1, GLU 1
KMQRMLLEKC2.009.721.231279.66Good0.35550%5/50.005/50.00GLN 1, GLY 0LYS 2, ARG 1, GLU 1
VLRQWLPTGT1.0010.110.371170.38Poor0.68840%5/50.005/50.00GLN 1, THR 2, GLY 1ARG 1
DMSKFPLKLR2.0010.010.981234.53Good0.33440%5/50.005/50.00SER 1, GLY 0LYS 2, ARG 1, ASP 1
MSKFPLKLRG3.0011.170.981176.49Good0.41140%5/50.005/50.00SER 1, GLY 1LYS 2, ARG 1
SKFPLKLRGT3.0011.170.981146.40Good0.31430%6/60.004/40.00SER 1, THR 1, GLY 1LYS 2, ARG 1
KFPLKLRGTA3.0011.170.981130.40Good0.34940%5/50.005/50.00THR 1, GLY 1LYS 2, ARG 1
MILSLLSKGR2.0011.010.611117.42Good0.60550%5/50.005/50.00SER 2, GLY 1LYS 1, ARG 1
LLSKGRLIIR3.0012.010.861168.49Good0.56550%5/50.005/50.00SER 1, GLY 1LYS 1, ARG 2
GRLIIRENNR2.0011.700.861240.43Good0.04330%7/70.003/30.00ASN 2, GLY 1ARG 3, GLU 1
RLIIRENNRV2.0011.700.861282.51Good0.16540%6/60.004/40.00ASN 2, GLY 0ARG 3, GLU 1
ORF6
LIIKNLSKSL2.0010.020.731128.42Good0.60450%5/50.005/50.00SER 2, ASN 1, GLY 0LYS 2
ORF7a
HVYQLRARSV2.5010.840.761228.42Good0.32640%5/50.005/50.00GLN 1, HIS 1, SER 1, GLY 0ARG 2
QLRARSVSPK3.0012.010.981141.34Good0.06430%6/60.004/40.00GLN 1, SER 2, GLY 0LYS 1, ARG 2
RARSVSPKLF3.0012.010.981160.39Good0.26540%5/50.005/50.00SER 2, GLY 0LYS 1, ARG 2
RSVSPKLFIR3.0012.010.861202.47Good0.41440%5/50.005/50.00SER 2, GLY 0LYS 1, ARG 2
ITLCFTLKRK3.0010.070.981222.56Good0.60650%5/50.005/50.00THR 2, GLY 0LYS 2, ARG 1
TLCFTLKRKT3.0010.070.981210.51Good0.45240%6/60.004/40.00THR 3, GLY 0LYS 2, ARG 1
LCFTLKRKTE2.009.361.111238.52Good0.36240%6/60.004/40.00THR 2, GLY 0LYS 2, ARG 1, GLU 1
ORF8
SKWYIRVGAR3.0011.010.861235.46Good0.34940%5/50.005/50.00SER 1, GLY 1LYS 1, ARG 2
KWYIRVGARK4.0011.101.221276.55Good0.25440%5/50.005/50.00GLY 1LYS 2, ARG 2
YIRVGARKSA3.0011.010.861120.32Good0.15540%5/50.005/50.00SER 1, GLY 1LYS 1, ARG 2

Evaluation of membrane-binding potential of CPPs

One of the principal criterions to design a potent CPP is the prediction of membrane-binding ability and cellular localization. Hence, the Boman index of each peptide was estimated using APD3 web server. The values higher than 2.48 kcal/ mol define high binding potential. For example, SSRSRNSSRN peptide derived from N-protein had the highest Boman index amongst all of the predicted CPPs (Boman Index: 7.5). Moreover, the D factor was calculated for each peptide based on net charge and μH. According to the computed D factor, CPPs can be divided into three different categories including D < 0.68 as non-lipid binding (helix/random coil), 0.68 < D < 1.34 as possible lipid-binding helix, and D > 1.34 as lipid-binding helix [46]. Additionally, the cellular localization of each CPP was evaluated by TMHMM server to determine the probability of CPPs which can enter the cell. The results of membrane-binding potential and cellular localization of CPPs were indicated in Table 3. Also, some examples of TMHMM prediction results were illustrated in Fig 1.

Prediction of cellular localization for CPPs using TMHMM web server: (A) EASKKPRQKR peptide containing tumor penetrating motif (RXXR); (B) GIEFLKRGDK peptide containing tumor homing motif (RGD); (C) RSGARSKQRR peptide with +5.00 net charge; (D) VVLKKLKKSL peptide with high half-life (~100 hour) in mammalian cells; (E) SSRSRNSSRN peptide with the highest Boman index (~7.5); (F) MCYKRNRATR peptide containing tumosr penetrating motif (RXXR). All of the prediction results showed the cell localization of CPPs.
Fig 1

Prediction of cellular localization for CPPs using TMHMM web server: (A) EASKKPRQKR peptide containing tumor penetrating motif (RXXR); (B) GIEFLKRGDK peptide containing tumor homing motif (RGD); (C) RSGARSKQRR peptide with +5.00 net charge; (D) VVLKKLKKSL peptide with high half-life (~100 hour) in mammalian cells; (E) SSRSRNSSRN peptide with the highest Boman index (~7.5); (F) MCYKRNRATR peptide containing tumosr penetrating motif (RXXR). All of the prediction results showed the cell localization of CPPs.

Table 3
Membrane-binding potential and cellular localization of CPPs.
EpitopeProtein-binding Potential (Boman index)Hydrophobic moment (μH)Membrane-binding potential (D factor)Cellular localization by TMHMM ServerTotal probability of N-in by TMHMM Server
S protein
NLTTRTQLPP2.490.1480.469Inside0.47745
RFQTLLALHR2.30.3421.147Inside0.48730
YLQPRTFLLK1.090.2250.8724Outside0.34806
SVYAWNRKRI3.240.2241.196Inside0.89106
YAWNRKRISN4.310.1621.142Inside0.91633
AWNRKRISNC4.170.2591.234Inside0.92814
WNRKRISNCV3.950.3001.273Inside0.91952
RQIAPGQTGK2.550.0810.736Inside0.71347
YNYLYRLFRK2.960.6901.641Inside0.74845
YLYRLFRKSN3.280.5671.525Inside0.69159
YRLFRKSNLK3.820.2751.5796Inside0.75816
RLFRKSNLKP3.810.3221.623Inside0.61242
RKSNLKPFER4.980.3681.337Inside0.70344
KKSTNLVKNK3.240.3551.655Inside0.87353
KSTNLVKNKC2.560.3771.345Inside0.85159
HADQLTPTWR2.990.4680.606Inside0.56152
YQTQTNSPRR5.620.3230.964Inside0.89727
TQTNSPRRAR6.360.2191.196Inside0.92515
TNSPRRARSV5.490.2921.265Inside0.85479
NSPRRARSVA5.050.3291.300Inside0.82719
PRRARSVASQ4.940.3021.275Inside0.83300
KQIYKTPPIK1.50.1941.173Inside0.77001
SQILPDPSKP1.670.4040.381Outside0.15396
RLITGRLQSL2.070.5020.897Inside0.47579
M protein
NRNRFLYIIK3.10.3461.316Inside0.81684
RNRFLYIIKL1.950.3261.297Inside0.66588
YIIKLIFLWL-2.910.4880.790Outside0.20334
KLIFLWLLWP-2.660.3040.616Outside0.07090
FIASFRLFAR1.080.5221.152Outside0.32626
ASFRLFARTR3.620.3431.313Inside0.67733
SFRLFARTRS4.140.3661.335Inside0.64273
FRLFARTRSM3.560.3501.320Inside0.67490
RLFARTRSMW3.630.5891.546Inside0.78030
FARTRSMWSF2.670.2770.921Inside0.62650
HGTILTRPLL0.410.2540.569Outside0.24888
GAVILRGHLR1.20.3230.964Outside0.42609
RIAGHHLGRC2.430.4231.059Inside0.64698
YSRYRIGNYK3.990.1411.123Inside0.89352
N protein
PQNQRNAPRI4.740.2430.889Inside0.80935
ERSGARSKQR6.670.1431.124Inside0.89938
RSGARSKQRR7.480.1141.757Inside0.94959
SGARSKQRRP5.990.1881.497Inside0.85655
GARSKQRRPQ6.20.1851.494Inside0.89829
ARSKQRRPQG6.20.1851.494Inside0.89829
RSKQRRPQGL5.890.2801.584Inside0.83224
SKQRRPQGLP4.40.2451.221Inside0.60745
KQRRPQGLPN4.720.2921.265Inside0.69009
RRPQGLPNNT4.530.4321.067Inside0.62344
QIGYYRRATR4.540.3831.351Inside0.93350
IGYYRRATRR5.480.4451.740Inside0.95251
GYYRRATRRI5.480.5641.852Inside0.95251
YYRRATRRIR7.070.5932.209Inside0.98065
YRRATRRIRG6.960.5652.183Inside0.96774
RRATRRIRGG6.850.4782.101Inside0.94656
RATRRIRGGD6.230.3651.334Inside0.90958
TRRIRGGDGK5.380.3141.286Inside0.85699
RIRGGDGKMK3.950.3211.293Inside0.80713
GKMKDLSPRW2.760.5231.153Inside0.53414
SQASSRSSSR5.390.1710.821Inside0.70911
ASSRSSSRSR6.330.1141.097Inside0.79316
SSRSSSRSRN7.180.1801.159Inside0.81855
SRSSSRSRNS7.180.1831.162Inside0.81855
RSSSRSRNSS7.180.1791.158Inside0.81855
SSSRSRNSSR7.180.1651.145Inside0.81855
SSRSRNSSRN7.50.1921.171Inside0.86592
RSRNSSRNST7.420.1941.173Inside0.90573
GSSRGTSPAR3.890.1560.807Inside0.52191
AALALLLLDR-0.630.1250.118Outside0.15140
ALALLLLDRL-0.950.2880.271Outside0.09169
KKSAAEASKK3.030.2771.251Inside0.85101
KSAAEASKKP2.480.3851.023Inside0.66436
SAAEASKKPR3.420.2840.928Inside0.71820
AAEASKKPRQ3.630.3060.948Inside0.79675
AEASKKPRQK4.360.2481.224Inside0.86032
EASKKPRQKR6.040.1651.475Inside0.92101
ASKKPRQKRT5.610.0961.740Inside0.94440
SKKPRQKRTA5.610.0601.706Inside0.94440
KKPRQKRTAT5.530.0871.732Inside0.96166
KPRQKRTATK5.530.0941.738Inside0.96166
PRQKRTATKA4.790.2021.510Inside0.94133
RQKRTATKAY4.810.3111.423Inside0.96930
RQGTDYKHWP3.880.3300.641Inside0.65834
FPPTEPKKDK3.170.0880.413Outside0.35377
PPTEPKKDKK4.020.2250.872Inside0.58321
PTEPKKDKKK4.580.2361.212Inside0.80442
TEPKKDKKKK5.130.1101.527Inside0.92302
EPKKDKKKKA4.70.1471.458Inside0.90887
PKKDKKKKAD4.890.1841.493Inside0.90457
KKDKKKKADE5.570.1331.115Inside0.93664
TQALPQRQKK3.840.3080.950Inside0.86179
ALPQRQKKQQ4.140.2431.219Inside0.86346
ORF3a
SASKIITLKK0.940.2431.219Inside0.75288
ASKIITLKKR2.090.3141.452Inside0.86807
SKIITLKKRW2.040.4921.784Inside0.86095
KIITLKKRWQ2.250.4851.777Inside0.90139
IITLKKRWQL1.210.3201.292Inside0.76749
KKRWQLALSK2.650.3351.636Inside0.79484
KRWQLALSKG20.4071.704Inside0.62646
VRIIMRLWLC0.010.4291.064Inside0.63104
RIIMRLWLCW0.180.6001.226Inside0.64902
IIMRLWLCWK-0.740.5171.148Inside0.61977
IMRLWLCWKC-0.380.3470.987Inside0.68839
MRLWLCWKCR1.590.1561.137Inside0.81046
RLWLCWKCRS2.170.1781.158Inside0.77912
LWLCWKCRSK1.230.2231.200Inside0.74360
WLCWKCRSKN2.390.0801.065Inside0.85315
LCWKCRSKNP2.620.1981.176Inside0.78747
CWKCRSKNPL2.620.2361.212Inside0.78747
KCRSKNPLLY2.50.1341.116Inside0.67216
Orf1ab
IKRSDARTAP4.150.2170.864Inside0.82802
KRSDARTAPH5.110.0390.696Inside0.81819
PVAYRKVLLR1.580.3131.285Inside0.60465
VAYRKVLLRK2.130.2081.516Inside0.80830
AYRKVLLRKN3.20.2241.531Inside0.85177
YRKVLLRKNG3.290.2411.547Inside0.79673
RKVLLRKNGN3.940.2001.508Inside0.80930
KVLLRKNGNK30.2341.540Inside0.77882
FEIKLAKKFD1.450.4120.718Inside0.48733
KTIQPRVEKK3.750.2891.262Inside0.88737
TIQPRVEKKK3.750.1611.141Inside0.88737
IQPRVEKKKL30.1031.087Inside0.78283
SGLKTILRKG1.530.5311.491Inside0.54410
LKTILRKGGR2.680.6251.91Inside0.71606
KTILRKGGRT3.430.4721.765Inside0.84956
GNFKVTKGKA1.510.1411.123Inside0.68622
FKVTKGKAKK2.050.3061.938Inside0.87336
KVTKGKAKKG2.250.2481.884Inside0.88617
KGKAKKGAWN2.10.1651.475Inside0.82016
GGAKLKALNL-0.250.0940.748Outside0.30336
SKGLYRKCVK2.390.5711.859Inside0.83410
KGLYRKCVKS2.390.5741.861Inside0.83410
GLYRKCVKSR3.320.4561.750Inside0.85872
GLLMPLKAPK-0.870.3050.947Outside0.15005
QRKQDDKKIK6.070.2231.2Inside0.95960
RKQDDKKIKA5.330.2271.204Inside0.94962
KQDDKKIKAC3.710.4201.056Inside0.92486
DITFLKKDAP1.640.2150.202Inside0.41432
MLAKALRKVP0.610.6411.595Inside0.57064
LAKALRKVPT1.10.6611.613Inside0.61542
EAKTVLKKCK1.950.5081.469Inside0.87393
AKTVLKKCKS1.610.5251.815Inside0.87056
KTVLKKCKSA1.610.5171.808Inside0.87056
KSAFYILPSI-0.70.3440.654Outside0.26827
KAIVSTIQRK2.180.4551.419Inside0.89354
STIQRKYKGI2.680.5471.506Inside0.87849
TIQRKYKGIK2.90.5331.823Inside0.93039
IQRKYKGIKI2.150.3561.656Inside0.90786
GARFYFYTSK1.80.1900.839Inside0.58982
ARYMRSLKVP2.580.4121.378Inside0.72252
GIEFLKRGDK2.680.4720.775Inside0.47568
DNLKTLLSLR2.210.3630.672Outside0.37423
YMSALNHTKK1.940.3731.012Inside0.74444
SALNHTKKWK2.480.4071.374Inside0.76830
ALNHTKKWKY2.150.3111.283Inside0.81149
LNHTKKWKYP2.340.2911.264Inside0.69869
NHTKKWKYPQ3.380.3621.331Inside0.82885
HTKKWKYPQV2.310.2171.194Inside0.78945
KKPASRELKV3.10.3171.289Inside0.71408
KPASRELKVT2.80.3560.996Inside0.66033
YTPSFKKGAK1.70.4251.391Inside0.60188
PSFKKGAKLL0.440.4881.450Outside0.28608
FKKGAKLLHK1.120.6391.923Inside0.56438
KKGAKLLHKP1.420.5441.833Inside0.55042
KGAKLLHKPI0.370.5901.546Inside0.43639
WCIRCLWSTK0.930.2230.870Inside0.79516
CIRCLWSTKP1.170.2980.941Inside0.70751
ANYAKPFLNK1.640.4081.045Inside0.53508
TNIVTRCLNR3.30.5621.190Inside0.89302
CTFTRSTNSR4.670.1400.792Inside0.87592
TCMMCYKRNR3.740.2281.205Inside0.96377
MCYKRNRATR5.420.2321.539Inside0.97415
CYKRNRATRV5.250.0841.399Inside0.97070
YKRNRATRVE6.060.0941.078Inside0.95678
KRNRATRVEC5.920.0771.062Inside0.96153
RNRATRVECT5.620.0320.690Inside0.95230
RDLSLQFKRP4.020.4541.088Inside0.49113
SLQFKRPINP2.320.3190.961Outside0.39508
HNIALIWNVK0.050.1880.507Inside0.60778
LSEQLRKQIR4.190.6861.307Inside0.75607
QLRKQIRSAA3.640.5271.487Inside0.86742
LRKQIRSAAK3.640.6211.906Inside0.89068
RKQIRSAAKK4.680.4512.075Inside0.95767
KQIRSAAKKN3.860.4131.709Inside0.93797
QIRSAAKKNN3.970.3191.291Inside0.92032
AAKKNNLPFK1.840.1981.176Inside0.63148
KKNNLPFKLT1.960.2381.214Inside0.54962
NNWLKQLIKV0.870.7281.347Inside0.65372
LAYYFMRFRR30.4691.432Inside0.71897
AYYFMRFRRA3.310.3031.276Inside0.82144
YYFMRFRRAF3.190.4781.441Inside0.72131
FMRFRRAFGE3.750.6001.226Inside0.52960
MRFRRAFGEY4.060.5041.135Inside0.70022
KEMYLKLRSD3.290.2650.580Inside0.65269
YNRYLALYNK2.250.5001.132Inside0.74756
RYLALYNKYK2.140.3921.360Inside0.80198
FRKMAFPSGK1.830.3131.285Inside0.47019
TANPKTPKYK2.670.0090.998Inside0.77069
ANPKTPKYKF2.120.1691.149Inside0.63687
PKTPKYKFVR2.720.2921.595Inside0.73005
KTPKYKFVRI2.230.3231.624Inside0.82704
RWFLNRFTTT3.090.3600.999Inside0.70898
FQSAVKRTIK2.370.6181.573Inside0.83635
SEVVLKKLKK1.440.5081.469Inside0.64932
VVLKKLKKSL0.270.6121.897Inside0.55852
VLKKLKKSLN1.340.7572.034Inside0.62971
KKLKKSLNVA1.650.5341.824Inside0.74490
DAAMQRKLEK3.620.3680.677Inside0.81844
AAMQRKLEKM2.510.5181.148Inside0.83287
MQRKLEKMAD3.560.6460.939Inside0.82292
YKQARSEDKR6.370.2330.879Inside0.92834
KQARSEDKRA6.170.2320.879Inside0.92248
QARSEDKRAK6.170.1860.835Inside0.92248
MLFTMLRKLD0.930.5620.860Outside0.39049
QDLKWARFPK2.820.3370.978Inside0.59730
DLKWARFPKS2.610.3560.996Inside0.48806
LKWARFPKSD2.610.3310.972Inside0.48806
KGFCDLKGKY1.440.4671.1Inside0.55047
GVSAARLTPC0.60.1090.432Inside0.44779
GFAKFLKTNC0.530.5301.160Inside0.51312
KTNCCRFQEK4.20.3330.974Inside0.92234
PHISRQRLTK4.170.1671.147Inside0.78638
HISRQRLTKY4.180.1901.169Inside0.87931
ISRQRLTKYT3.970.2081.186Inside0.90259
SRQRLTKYTM4.230.2311.208Inside0.90877
RQRLTKYTMA3.710.2101.188Inside0.92213
GERVRQALLK3.110.4011.038Inside0.66110
RVRQALLKTV2.370.4901.452Inside0.78888
KPYIKWDLLK0.840.1430.794Inside0.49602
RLKLFDRYFK3.40.6221.577Inside0.61889
KLFDRYFKYW2.180.8891.499Inside0.59390
FPFNKWGKAR2.160.3381.309Inside0.52642
KWGKARLYYD2.50.1770.827Inside0.72287
YAISAKNRAR3.520.0761.061Inside0.91112
AISAKNRART3.760.0371.024Inside0.91919
KNRARTVAGV3.190.3151.287Inside0.88250
NRQFHQKLLK3.550.4361.401Inside0.73407
RQFHQKLLKS3.230.4951.457Inside0.65716
RIMASLVLAR0.840.1800.829Inside0.57528
RNLQHRLYEC4.250.5190.819Inside0.77699
RLYECLYRNR4.730.4301.065Inside0.85428
SLRCGACIRR3.30.3561.326Inside0.83575
RCGACIRRPF3.150.6331.587Inside0.77458
CGACIRRPFL1.170.4221.058Inside0.52389
GACIRRPFLC1.170.2690.913Inside0.52389
ACIRRPFLCC1.130.4161.052Inside0.66539
CIRRPFLCCK1.870.4931.455Inside0.75457
IRRPFLCCKC1.870.2981.271Inside0.75457
RRPFLCCKCC2.230.3471.317Inside0.81002
MSYYCKSHKP1.920.2710.915Inside0.68047
ANTCTERLKL2.610.3480.988Inside0.76670
SWEVGKPRPP2.330.1230.446Outside0.22968
VGKPRPPLNR3.210.4031.370Inside0.41222
GKPRPPLNRN4.280.2611.236Inside0.48502
KALKYLPIDK0.890.1540.805Inside0.53339
DKCSRIIPAR3.450.4181.054Inside0.82505
KCSRIIPARA2.40.3761.344Inside0.83189
CSRIIPARAR3.340.4251.391Inside0.84740
SRIIPARARV3.060.2891.262Inside0.80072
RIIPARARVE3.40.2330.879Inside0.79867
SVVNARLRAK2.880.1441.125Inside0.81132
VVNARLRAKH3.000.1381.120Inside0.83250
VNARLRAKHY3.420.1001.084Inside0.86059
NARLRAKHYV3.420.0571.043Inside0.86059
PAPRTLLTKG1.30.2420.888Outside0.35023
APRTLLTKGT1.550.3130.955Inside0.54170
FNSVCRLMKT1.750.6031.229Inside0.71012
FLGTCRRCPA1.920.6061.232Inside0.60210
DNKLKAHKDK4.420.2690.913Inside0.80851
KLKAHKDKSA3.040.2171.194Inside0.79044
FLTRNPAWRK3.250.2561.231Inside0.70721
RNPAWRKAVF2.90.1671.147Inside0.75095
GIPKDMTYRR3.860.1810.830Inside0.81853
DMTYRRLISM3.010.3340.645Inside0.78592
GNPKAIKCVP0.470.3010.944Inside0.53539
WNTFTRLQSL2.040.4320.737Inside0.51104
ELWAKRNIKP2.540.2480.894Inside0.69594
LWAKRNIKPV1.460.3071.279Inside0.70434
WAKRNIKPVP1.950.4351.4Inside0.69474
RNIKPVPEVK2.640.3651.004Inside0.65866
LLIGLAKRFK0.060.5561.514Outside0.34306
GLAKRFKESP2.550.5671.195Inside0.41824
KMQRMLLEKC2.250.5341.164Inside0.77714
VLRQWLPTGT0.840.4420.747Inside0.37448
DMSKFPLKLR2.290.4381.073Outside0.39910
MSKFPLKLRG1.330.4251.391Outside0.33087
SKFPLKLRGT1.820.3121.284Outside0.37440
KFPLKLRGTA1.30.3371.308Outside0.41667
MILSLLSKGR0.430.3831.021Outside0.30296
LLSKGRLIIR1.320.4191.385Outside0.44682
GRLIIRENNR4.910.3360.977Inside0.81939
RLIIRENNRV4.60.4431.078Inside0.85576
ORF6
LIIKNLSKSL00.6011.227Outside0.38147
ORF7a
HVYQLRARSV2.870.2050.853Inside0.75260
QLRARSVSPK3.690.0811.066Inside0.70446
RARSVSPKLF2.840.3441.314Inside0.52495
RSVSPKLFIR2.530.1581.139Inside0.51018
ITLCFTLKRK1.210.2721.246Inside0.72907
TLCFTLKRKT1.960.2801.254Inside0.78296
LCFTLKRKTE2.380.3410.981Inside0.71141
ORF8
SKWYIRVGAR2.480.3031.276Inside0.82389
KWYIRVGARK2.70.2081.516Inside0.89799
YIRVGARKSA2.540.2731.247Inside0.83725

Assessment of the immunogenicity

As we mentioned earlier, it is important that CPPs as a delivery system should not have any immune activity. Hence, we analyzed the immunogenicity activity of each peptide using IEDB Immunogenicity Predictor. The results were listed in Table 4.

Table 4
Evaluation of immunogenicity, toxicity, allergenicity, half-life and hemolytic potency.
EpitopeImmunogenicity (IEDB)ToxicityAllergenicity (AllerTop)Allergenicity (AllergenFP)Half-life in E.coliHalf-life in mammalianHemoPI
S protein
NLTTRTQLPP0.01498Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN--0.49
RFQTLLALHR0.02623Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
YLQPRTFLLK0.1338Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
SVYAWNRKRI0.14453Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.50
YAWNRKRISN-0.02983Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
AWNRKRISNC-0.12774Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
WNRKRISNCV-0.21289Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.49
RQIAPGQTGK0.04829Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.48
YNYLYRLFRK0.15304Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
YLYRLFRKSN-0.07586Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
YRLFRKSNLK-0.21307Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.44
RLFRKSNLKP-0.42247Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
RKSNLKPFER-0.13415Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
KKSTNLVKNK-0.17866Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
KSTNLVKNKC-0.29897Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
HADQLTPTWR0.06938Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 3.5 hour0.49
YQTQTNSPRR-0.20731Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.49
TQTNSPRRAR-0.05055Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 7.2 hour0.49
TNSPRRARSV0.01979Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 7.2 hour0.51
NSPRRARSVA0.0702Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 7.2 hour0.50
PRRARSVASQ-0.07931Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN--0.49
KQIYKTPPIK-0.07476Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >0 hour~ >20 hour0.49
SQILPDPSKP-0.23322Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.49
RLITGRLQSL-0.0392Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
M protein
NRNRFLYIIK0.33978Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN--0.49
RNRFLYIIKL0.2318Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.50
YIIKLIFLWL0.17526Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
KLIFLWLLWP0.47552Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
FIASFRLFAR0.12185Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.1 hour0.49
ASFRLFARTR0.29647Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 4.4 hour0.49
SFRLFARTRS0.26946Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.49
FRLFARTRSM0.18626Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.1 hour0.49
RLFARTRSMW-0.02793Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
FARTRSMWSF-0.12986Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.1 hour0.49
HGTILTRPLL0.2064Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 3.5 hour0.49
GAVILRGHLR0.23964Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 30 hour0.50
RIAGHHLGRC0.1582Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.50
YSRYRIGNYK0.21736Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.49
N protein
PQNQRNAPRI-0.01685Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >0 hour~ >20 hour0.49
ERSGARSKQR-0.33651Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1 hour0.49
RSGARSKQRR-0.33085Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
SGARSKQRRP-0.34144Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.49
GARSKQRRPQ-0.38655Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
ARSKQRRPQG-0.36142Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 4.4 hour0.49
RSKQRRPQGL-0.17416Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.48
SKQRRPQGLP-0.03284Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.48
KQRRPQGLPN-0.03866Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
RRPQGLPNNT-0.11764Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
QIGYYRRATR0.1585Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 0.8 hour0.49
IGYYRRATRR0.19571Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 20 hour0.49
GYYRRATRRI0.24984Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
YYRRATRRIR0.31494Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
YRRATRRIRG0.33565Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.48
RRATRRIRGG0.34132Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.48
RATRRIRGGD0.3418Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
TRRIRGGDGK0.30454Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 7.2 hour0.49
RIRGGDGKMK-0.1472Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.48
GKMKDLSPRW-0.39805Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
SQASSRSSSR-0.65648Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.49
ASSRSSSRSR-0.53253Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
SSRSSSRSRN-0.53253Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.49
SRSSSRSRNS-0.4467Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.49
RSSSRSRNSS-0.38427Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
SSSRSRNSSR-0.35469Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.49
SSRSRNSSRN-0.37068Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.49
RSRNSSRNST-0.36531Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
GSSRGTSPAR-0.07305Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
AALALLLLDR0.00733Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 4.4 hour0.49
ALALLLLDRL0.01846Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
KKSAAEASKK-0.10752Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
KSAAEASKKP-0.27606Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
SAAEASKKPR-0.40103Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.49
AAEASKKPRQ-0.48135Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
AEASKKPRQK-0.60821Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 4.4 hour0.49
EASKKPRQKR-0.66654Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1 hour0.49
ASKKPRQKRT-0.5082Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 4.4 hour0.49
SKKPRQKRTA-0.2802Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.49
KKPRQKRTAT-0.16998Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
KPRQKRTATK-0.16712Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
PRQKRTATKA-0.22281Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >0 hour~ >20 hour0.49
RQKRTATKAY-0.06462Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
RQGTDYKHWP0.02178Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.48
FPPTEPKKDK-0.24988Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.1 hour0.49
PPTEPKKDKK-0.41773Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >0 hour~ >20 hour0.49
PTEPKKDKKK-0.68578Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >0 hour~ >20 hour0.49
TEPKKDKKKK-0.92Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 7.2 hour0.49
EPKKDKKKKA-0.9864Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1 hour0.49
PKKDKKKKAD-0.82982Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >0 hour~ >20 hour0.49
KKDKKKKADE-0.78682Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
TQALPQRQKK-0.2971Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 7.2 hour0.49
ALPQRQKKQQ-0.63524Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
ORF3a
SASKIITLKK-0.11032Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.56
ASKIITLKKR-0.08712Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.63
SKIITLKKRW-0.15064Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.49
KIITLKKRWQ-0.16844Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.48
IITLKKRWQL-0.25058Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ >20 hour0.50
KKRWQLALSK0.0469Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.48
KRWQLALSKG-0.29342Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.48
VRIIMRLWLC0.22654Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 100 hour0.49
RIIMRLWLCW0.07375Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
IIMRLWLCWK0.27346Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 20 hour0.49
IMRLWLCWKC0.22073Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 20 hour0.49
MRLWLCWKCR0.151Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
RLWLCWKCRS0.00568ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
LWLCWKCRSK-0.15588ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 5.5 hour0.48
WLCWKCRSKN-0.27401ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
LCWKCRSKNP-0.48871ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 5.5 hour0.48
CWKCRSKNPL-0.44989ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.2 hour0.48
KCRSKNPLLY-0.39225ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.48
Orf1ab
IKRSDARTAP0.01437Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 20 hour0.48
KRSDARTAPH0.1202Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
PVAYRKVLLR-0.1276Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >0 hour~> 20 hour0.49
VAYRKVLLRK-0.10848Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >0 hour~ 100 hour0.48
AYRKVLLRKN-0.26356Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.48
YRKVLLRKNG-0.18712Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.48
RKVLLRKNGN-0.14682Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
KVLLRKNGNK-0.15563Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.48
FEIKLAKKFD-0.4631Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.1 hour0.47
KTIQPRVEKK-0.0364Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.48
TIQPRVEKKK-0.17191Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 7.2 hour0.48
IQPRVEKKKL-0.32482Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 20 hour0.46
SGLKTILRKG-0.14596Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.52
LKTILRKGGR0.03152Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 5.5 hour0.47
KTILRKGGRT-0.03682Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.48
GNFKVTKGKA-0.4014Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.48
FKVTKGKAKK-0.42052Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.1 hour0.49
KVTKGKAKKG-0.65257Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
KGKAKKGAWN-0.25629Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
GGAKLKALNL-0.40141Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 30 hour0.53
SKGLYRKCVK-0.17774Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.47
KGLYRKCVKS-0.30883Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.47
GLYRKCVKSR-0.45142Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.45
GLLMPLKAPK-0.37836Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 30 hour0.49
QRKQDDKKIK-0.4506Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 0.8 hour0.49
RKQDDKKIKA-0.42036Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
KQDDKKIKAC-0.42434Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
DITFLKKDAP-0.25182Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.1 hour0.49
MLAKALRKVP-0.28616Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 30 hour0.49
LAKALRKVPT-0.16567Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 5.5 hour0.50
EAKTVLKKCK-0.41804Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1 hour0.49
AKTVLKKCKS-0.54116Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 4.4 hour0.49
KTVLKKCKSA-0.74717Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
KSAFYILPSI0.14004Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
KAIVSTIQRK0.0192Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
STIQRKYKGI-0.39864Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.48
TIQRKYKGIK-0.29576Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 7.2 hour0.49
IQRKYKGIKI-0.39558Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 20 hour0.49
GARFYFYTSK0.17762Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
ARYMRSLKVP-0.45692Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 4.4 hour0.49
GIEFLKRGDK0.01978Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.47
DNLKTLLSLR-0.35014Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.1 hour0.49
YMSALNHTKK-0.09422Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.49
SALNHTKKWK-0.19639Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.50
ALNHTKKWKY-0.28381Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
LNHTKKWKYP-0.34609Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 5.5 hour0.49
NHTKKWKYPQ-0.4113Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN--0.49
HTKKWKYPQV-0.36182Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 3.5 hour0.49
KKPASRELKV-0.11604Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.45
KPASRELKVT-0.17419Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
YTPSFKKGAK-0.41761Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
PSFKKGAKLL-0.50765Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >0 hour~ >20 hour0.51
FKKGAKLLHK-0.2087Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.1 hour0.48
KKGAKLLHKP-0.27957Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.47
KGAKLLHKPI-0.38393Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.44
WCIRCLWSTK0.12355ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
CIRCLWSTKP-0.08152Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.2 hour0.48
ANYAKPFLNK-0.08557Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
TNIVTRCLNR0.10905Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 7.2 hour0.49
CTFTRSTNSR-0.09922Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.2 hour0.49
TCMMCYKRNR-0.4529ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 7.2 hour0.49
MCYKRNRATR-0.06968ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 30 hour0.48
CYKRNRATRV0.12601ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.2 hour0.49
YKRNRATRVE0.20313Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.49
KRNRATRVEC0.26794Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
RNRATRVECT0.23623Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
RDLSLQFKRP-0.33523Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
SLQFKRPINP0.0187Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.48
HNIALIWNVK0.42854Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 3.5 hour0.49
LSEQLRKQIR-0.26746Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 5.5 hour0.49
QLRKQIRSAA-0.25144Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 min~ 0.8 hour0.44
LRKQIRSAAK-0.10641Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 5.5 hour0.37
RKQIRSAAKK-0.07053Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.48
KQIRSAAKKN-0.29889Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.50
QIRSAAKKNN-0.46225Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 0.8 hour0.49
AAKKNNLPFK-0.251Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
KKNNLPFKLT-0.10849Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
NNWLKQLIKV-0.28618Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN--0.49
LAYYFMRFRR0.11584Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 5.5 hour0.49
AYYFMRFRRA0.18012Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
YYFMRFRRAF0.14096Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
FMRFRRAFGE0.39083Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.1 hour0.49
MRFRRAFGEY0.37588Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
KEMYLKLRSD-0.34494Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
YNRYLALYNK0.02304Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
RYLALYNKYK-0.16888Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
FRKMAFPSGK-0.22486Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.1 hour0.50
TANPKTPKYK-0.38006Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 7.2 hour0.49
ANPKTPKYKF-0.52572Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
PKTPKYKFVR-0.29224Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >0 hour~ >30 hour0.49
KTPKYKFVRI-0.25892Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
RWFLNRFTTT0.23658Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
FQSAVKRTIK-0.02489Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.1 hour0.50
SEVVLKKLKK-0.50422Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.48
VVLKKLKKSL-0.92306Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 100 hour0.48
VLKKLKKSLN-0.8569Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 100 hour0.48
KKLKKSLNVA-0.58348Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.47
DAAMQRKLEK-0.38026Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.1 hour0.49
AAMQRKLEKM-0.3851Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 4.4 hour0.49
MQRKLEKMAD-0.44184Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 30 hour0.49
YKQARSEDKR-0.12196Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.49
KQARSEDKRA-0.1297Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
QARSEDKRAK-0.16703Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 0.8 hour0.49
MLFTMLRKLD-0.2445Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
QDLKWARFPK0.17424Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 0.8 hour0.48
DLKWARFPKS0.21623Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.1 hour0.49
LKWARFPKSD-0.01343Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 5.5 hour0.49
KGFCDLKGKY-0.30585Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
GVSAARLTPC0.09001Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.48
GFAKFLKTNC-0.27512Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
KTNCCRFQEK0.01249ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.48
PHISRQRLTK-0.12363Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >0 hour~ >20 hour0.47
HISRQRLTKY-0.1677Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 3.5 hour0.48
ISRQRLTKYT-0.20778Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 20 hour0.49
SRQRLTKYTM-0.14196Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.49
RQRLTKYTMA-0.23988Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
GERVRQALLK0.01693Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 30 hour0.48
RVRQALLKTV-0.24222Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.48
KPYIKWDLLK0.14346Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.48
RLKLFDRYFK0.16844Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.46
KLFDRYFKYW0.03316Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
FPFNKWGKAR-0.09005Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.1 hour0.49
KWGKARLYYD-0.13322Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
YAISAKNRAR-0.23472Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.49
AISAKNRART-0.11865Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.49
KNRARTVAGV0.23605Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
NRQFHQKLLK-0.21994Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN--0.49
RQFHQKLLKS-0.39805Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
RIMASLVLAR-0.13717Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.48
RNLQHRLYEC0.00668ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.49
RLYECLYRNR0.07267ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
SLRCGACIRR0.12546Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.46
RCGACIRRPF0.21339Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.48
CGACIRRPFL0.24621Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.2 hour0.43
GACIRRPFLC0.2991Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.43
ACIRRPFLCC0.20422ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 min~ 4.4 hour0.48
CIRRPFLCCK0.08464ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.2 hour0.49
IRRPFLCCKC-0.11341ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 20 hour0.49
RRPFLCCKCC-0.21335ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
MSYYCKSHKP-0.52185Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
ANTCTERLKL0.00701Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 4.4 hour0.49
SWEVGKPRPP-0.0762Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.49
VGKPRPPLNR-0.06514Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 100 hour0.49
GKPRPPLNRN0.04122Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 30 hour0.49
KALKYLPIDK-0.12016Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.48
DKCSRIIPAR0.13481Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.1 hour0.48
KCSRIIPARA0.3104Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.48
CSRIIPARAR0.37289Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.2 hour0.49
SRIIPARARV0.3164Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.49
RIIPARARVE0.22517Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
SVVNARLRAK0.15149Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.9 hour0.48
VVNARLRAKH0.03261Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 100 hour0.49
VNARLRAKHY-0.02189Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 100 hour0.48
NARLRAKHYV-0.08372Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN--0.48
PAPRTLLTKG-0.0282Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >0 hour~ >20 hour0.49
APRTLLTKGT-0.0914Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 4.4 hour0.49
FNSVCRLMKT-0.2989Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.1 hour0.48
FLGTCRRCPA0.0447Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.1 hour0.47
DNKLKAHKDK-0.39165Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.1 hour0.49
KLKAHKDKSA-0.46691Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.48
FLTRNPAWRK0.30159Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.1 hour0.48
RNPAWRKAVF0.15601Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.48
GIPKDMTYRR-0.30634Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
DMTYRRLISM0.1149Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.1 hour0.49
GNPKAIKCVP-0.27728Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.48
WNTFTRLQSL0.01374Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.49
ELWAKRNIKP-0.0681Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1 hour0.49
LWAKRNIKPV-0.2234Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 5.5 hour0.50
WAKRNIKPVP-0.08286Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 2.8 hour0.49
RNIKPVPEVK-0.04622Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.48
LLIGLAKRFK0.01368Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ 2 min~ 5.5 hour0.52
GLAKRFKESP-0.25506Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 30 hour0.52
KMQRMLLEKC-0.21926Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.49
VLRQWLPTGT0.14726Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 100 hour0.49
DMSKFPLKLR-0.36642Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ >10 hour~ 1.1 hour0.49
MSKFPLKLRG-0.15592Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 30 hour0.52
SKFPLKLRGT-0.14092Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.53
KFPLKLRGTA-0.13556Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1.3 hour0.52
MILSLLSKGR-0.5096Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.50
LLSKGRLIIR-0.00766Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 5.5 hour0.50
GRLIIRENNR0.39533Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 30 hour0.49
RLIIRENNRV0.34371Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1 hour0.49
ORF6
LIIKNLSKSL-0.62529Non-ToxinPROBABLE ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 5.5 hour0.49
ORF7a
HVYQLRARSV-0.09431Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 min~ 3.5 hour0.49
QLRARSVSPK-0.16177Non-ToxinPROBABLE ALLERGENPROBABLE ALLERGEN~ >10 hour~ 0.8 hour0.47
RARSVSPKLF-0.46949Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.48
RSVSPKLFIR-0.20775Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 1 hour0.48
ITLCFTLKRK-0.06825Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 20 hour0.49
TLCFTLKRKT-0.15802Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 7.2 hour0.49
LCFTLKRKTE-0.25434Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 5.5 hour0.49
ORF8
SKWYIRVGAR0.3385Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ >10 hour~ 1.9 hour0.49
KWYIRVGARK0.31848Non-ToxinPROBABLE Non-ALLERGENPROBABLE ALLERGEN~ 2 min~ 1.3 hour0.49
YIRVGARKSA-0.1005Non-ToxinPROBABLE Non-ALLERGENPROBABLE Non-ALLERGEN~ 2 min~ 2.8 hour0.48

Determination of toxicity and allergenicity

The toxicity and allergenicity of each peptide were determined using diverse web servers (Table 4). In detail, most of the predicted CPPs were non-toxic. The toxic CPPs were derived from ORF3a and Orf1ab polyproteins. Furthermore, there are some differences between allergenicity prediction by AllerTop, and AllergenFP web servers. Some CPPs were determined as probable allergen by AllerTop, whereas they were identified as probable non-allergen by AllergenFP. It is rational to select CPPs which were determined as probable non-allergen by both web servers.

Estimation of hemolytic potency and half-life

It should be considered that high hydrophobicity of a peptide enhances its probability of hydrolysis in the host; therefore, the probability of hydrolysis and half-life of each peptide in E.coli and mammalian were evaluated using HemoPI and ProtLifePred web servers (Table 4). The results of hemolytic potency vary between 0 and 1 (i.e., 0 very unlikely to be hemolytic, and 1 very likely to be hemolytic). For example, seven predicted CPPs had the highest half-life in mammalian cells (~ 100 hours) which all of them were derived from Orf1ab polyprotein including VAYRKVLLRK, VVLKKLKKSL, VLKKLKKSLN, VGKPRPPLNR, VVNARLRAKH, VNARLRAKHY, and VLRQWLPTGT peptides.

Prediction of CPP structure

The 3D spatial shapes of CPPs were predicted by PEP-FOLD3 web server (Fig 2). Also, the helical wheel projection of these short peptides were obtained via Heliquest web server as indicated in Fig 3. A peptide comprising at least five adjacent hydrophobic residues (such as Leu, Ile, Ala, Val, Pro, Met, Phe, Trp, and Tyr) illustrates a hydrophobic face on a helical wheel projection [46].

The 3D spatial shape of CPPs predicted by PEP-FOLD3 web server: (A) EASKKPRQKR peptide containing tumor penetrating motif (RXXR); (B) GIEFLKRGDK peptide containing tumor homing motif (RGD); (C) RSGARSKQRR peptide with +5.00 net charge; (D) VVLKKLKKSL peptide with high half-life (~100 hour) in mammalian cells; (E) SSRSRNSSRN peptide with the highest Boman index (~7.5); (F) MCYKRNRATR peptide containing tumor penetrating motif (RXXR).
Fig 2

The 3D spatial shape of CPPs predicted by PEP-FOLD3 web server: (A) EASKKPRQKR peptide containing tumor penetrating motif (RXXR); (B) GIEFLKRGDK peptide containing tumor homing motif (RGD); (C) RSGARSKQRR peptide with +5.00 net charge; (D) VVLKKLKKSL peptide with high half-life (~100 hour) in mammalian cells; (E) SSRSRNSSRN peptide with the highest Boman index (~7.5); (F) MCYKRNRATR peptide containing tumor penetrating motif (RXXR).

Helical wheel projection of the six selected CPPs by HeliQuest: These data indicated the possible amphipathic α-helical conformation of the selected CPPs: (A) EASKKPRQKR peptide containing tumor penetrating motif (RXXR); (B) GIEFLKRGDK peptide containing tumor homing motif (RGD); (C) RSGARSKQRR peptide with +5.00 net charge; (D) VVLKKLKKSL peptide with high half-life (~100 hour) in mammalian cells; (E) SSRSRNSSRN peptide with the highest Boman index (~7.5); (F) MCYKRNRATR peptide containing tumor penetrating motif (RXXR). The structural motifs were shown as hydrophobic (yellow) and cationic (blue). Arrow illustrates direction of the hydrophobic moment (μH).
Fig 3

Helical wheel projection of the six selected CPPs by HeliQuest: These data indicated the possible amphipathic α-helical conformation of the selected CPPs: (A) EASKKPRQKR peptide containing tumor penetrating motif (RXXR); (B) GIEFLKRGDK peptide containing tumor homing motif (RGD); (C) RSGARSKQRR peptide with +5.00 net charge; (D) VVLKKLKKSL peptide with high half-life (~100 hour) in mammalian cells; (E) SSRSRNSSRN peptide with the highest Boman index (~7.5); (F) MCYKRNRATR peptide containing tumor penetrating motif (RXXR). The structural motifs were shown as hydrophobic (yellow) and cationic (blue). Arrow illustrates direction of the hydrophobic moment (μH).

Discussion

Vaccination is one of the most effective strategies for control of dangerous pathogens. A potent vaccine must stimulate strong humoral and cellular immune responses in host [56]. The vaccine efficacy relies on various factors including the selected antigen, adjuvant and delivery system [57]. Therefore, many researchers have focused on development of novel and powerful delivery systems [9,5860]. Since the discovery of CPPs, these short peptides were considered as a significant delivery system to enter diverse types of cargoes into cells due to their high cellular uptake efficiency. Several viruses such as HIV-1, Influenza A virus subtype H5N1, Dengue virus and HSV-1 contain CPPs in their proteome [11,30,34,61].

The bioinformatics strategies take scientists one step forward in screening and evaluating CPPs. Hence, the current study was planned to screen and identify novel and potent CPPs in the proteome of SARS-CoV-2 using in silico tools. To achieve this aim, we extracted the sequences of S, M, N, E, ORF1ab, ORF3a, ORF6, ORF7a, ORF8, and ORF10 proteins and submitted to CellPPD web server. The CellPPD is a support vector machine (SVM)-based prediction approach which was established to predict highly efficient cell penetrating peptides. The CellPPD method was based on binary profile of peptides that settle the information of both composition and order of residues in peptides [40]. The output of analysis using CellPPD web server was a large number of CPPs which subjected to several web servers for further analysis such as their physicochemical properties, uptake efficiency, toxicity, allergenicity, cellular localization, tendency for binding to plasma membrane, and prediction of 3D structure. Our results showed that the proteome of SARS-CoV-2 contains a large number of cell penetrating peptides. Most of the predicted CPPs were originated from Orf1ab polyprotein. Orf1ab polyprotein forms about two thirds of the SARS-CoV-2 genome that is translated into two polypeptides such as pp1a and pp1b. Next, these two polypeptides are processed and cleaved into sixteen non-structural proteins (nsp). Non-structural proteins possess crucial functions in the replication, transcription and pathogenesis of viral RNA [29]. Despite Orf1ab polyprotein, our data indicated that no CPP was found in the E protein. This protein is responsible for virus production and maturation [28]. Herein, twenty-four CPPs were predicted in spike (S) protein, as well. Furthermore, most of the predicted CPPs in S protein are amphipathic in nature. On the other hand, most of the predicted CPPs showed high uptake efficiency using in silico approaches. The studies demonstrated that several factors affect the uptake efficiency such as the number of arginine, the existence of tryptophan and its affinity to form helical structure, and orientation of tryptophan and arginine around the helix [6264]. In addition, it should be considered that CPPs because of their natural pore-forming propensity and high hydrophobic moment (μH) could damage or destabilize the lipid bilayers irreversibly and so they showed cytotoxic effects. Hence, minimizing μH should be performed to reduce the membrane-disturbing by CPPs [65,66]. Our data indicated that most of the CPPs predicted from the proteome of SARS-CoV-2 were not toxic and allergen, and had appropriate half-life, as well as they could bind to plasma membrane with high potential and subsequently penetrate into cells. For example, Kajiwara et al. showed that H5N1 highly pathogenic avian influenza virus (HPAIV) infects host cells by recruiting CPP activity of the C-terminal domain of HA1 protein (HA314-346) [61]. Moreover, the N-terminal tail of capsid protein (CaP) from the plant-infecting brome mosaic virus (BMV) containing the arginine-rich motif was essential for penetration through cellular membranes [67]. Thus, it is possible that CPPs found in the SARS-CoV-2 proteome possess the potency for virus penetration into host cells.

On the other hand, CPPs are not cell-specific and thus they are internalized in most of the cell types through receptor-independent approach. Hence, to determine CPPs that might be cancer-specific or might enter cancerous cells effectively, the peptide sequence should possess the tumor homing motif (RGD) and/or tumor penetrating motif (RXXR). Moreover, the peptides harboring RXXR motif at their C-terminal region could enter tumor cells through binding to neuropilin receptor which was commonly expressed at the surface of tumor cells [19]. In our study, one of the SARS-CoV-2-derived CPPs (i.e., GIEFLKRGDK) contains RGD motif. This CPP with +1.00 net charge was soluble in water, non-toxic, and its half-life was about 30 hours in mammalian. Its cellular localization was predicted using TMHMM server. Interestingly, two CPPs such as EASKKPRQKR and MCYKRNRATR peptides included RXXR motif at their C-terminal regions. In detail, EASKKPRQKR peptide had +4.00 net charge and good water solubility. This peptide was non-toxic and non-allergen with about one hour half-life in mammalian. Also, the Boman index was 6.04 for this CPP (i.e., the values higher than 2.48 kcal/mol showed high binding potential), and its cellular localization was confirmed by TMHMM web server. Moreover, MCYKRNRATR peptide had +4.00 net charge and good water solubility. But this CPP was predicted as a toxic and allergen peptide with the estimated Boman index about 5.42. Additionally, TMHMM web server predicted its localization inside the cell. Therefore, based on our data, the efficiency of GIEFLKRGDK and EASKKPRQKR peptides can be further evaluated in vitro and in vivo as a delivery system in cancer therapy.

In the present study, only CPPs with 10 residues in length were predicted. As known, CPPs contain 5–50 residues in length [11]. Thus, we can design novel CPPs with more length and higher efficiency by addition of some sequences for delivery of different cargoes. For instance, we can add a hydrophilic lysine-rich domain derived from NLS of SV40 large T-antigen (KKKRKV) and a spacer domain (WSQP) to improve the efficiency of CPPs in DNA delivery as used in other studies [33]. In this study, as an example, by merging 11 overlapped CPPs derived from N protein such as KKSAAEASKK, KSAAEASKKP, SAAEASKKPR, AAEASKKPRQ, AEASKKPRQK, EASKKPRQKR, ASKKPRQKRT, SKKPRQKRTA, KKPRQKRTAT, KPRQKRTATK, and PRQKRTATKA peptides (with net charges of +4.00 and +5.00), a novel CPP was designed with 21 residues in length (i.e., KKSAAEASKKPRQKRTATKAY). This CPP had +7.00 net charge and good water solubility. Moreover, it was non-allergen and non-toxic with immunogenicity score about -0.70123 and D factor about 2.46 which would be located into cells as predicted by TMHMM web server. Surprisingly, when the SV40 large T-antigen NLS sequence and a spacer domain were conjugated to this CPP, we had a new CPP with 31 amino acids in length (i.e., KKSAAEASKKPRQKRTATKAYWSQPKKKRKV), +12.00 net charge, and good water solubility. This peptide was non-allergen and non-toxic with immunogenicity score about -1.49065 and D factor about 4.11, which was localized into cells as predicted by TMHMM web server. Indeed, using the conjugation of NLS and spacer to the designed CPP, the net charge and the probability of cellular localization inside cells were enhanced. Our predicted and designed CPP is similar to MPG CPP (27 residues in length, and +4.00 net charge) composed of peptide derived from HIV-1 glycoprotein 41, SV40 NLS and spacer domain. The MPG peptide was reported for delivery of DNA-based vaccine both in vitro and in vivo [33,68,69].

Conclusion

In conclusion, novel and potent CPPs derived from the proteome of SARS-CoV-2 were identified using in silico methods. It is possible for relationship between these CPPs and rapid spreading the virus in host. Moreover, we designed a long and novel CPP conjugated to SV40 NLS and spacer domain that had high binding ability to membrane and localization inside cells. The designed CPP was similar to MPG CPP. This CPP can be further evaluated for DNA delivery in vitro and in vivo in future. Generally, the predicted and designed CPPs derived from the proteome of SARS-CoV-2 with different properties can be applied to deliver different cargoes in vaccine and drug development.

References

HFFlorindo , RKleiner, DVaskovich-Koubi, RCAcúrcio, BCarreira, EYeini, et al Immune-mediated approaches against COVID-19. Nature Nanotechnology. 2020; 15: 630645. 10.1038/s41565-020-0732-3

GZareba. A new combination vaccine for measles, mumps, rubella and varicella. Drugs Today. 2006; 42: 321329. 10.1358/dot.2006.42.5.973586

KKardani, PBasimi, MFekri, ABolhassani. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev. Clin. Pharmacol. 2020; 13 (9): 10011046.

AGarg, HKDewangan. Nanoparticles as adjuvants in vaccine delivery. Crit. Rev. Ther. Drug. 2020; 37 (2): 183204. 10.1615/CritRevTherDrugCarrierSyst.2020033273

RJNevagi, MSkwarczynski, IToth. Polymers for subunit vaccine delivery. Eur. Polym. J. 2019; 114: 397410.

SŞenel, SYüksel. Chitosan-based particulate systems for drug and vaccine delivery in the treatment and prevention of neglected tropical diseases. Drug. Deliv. Transl. Res. 2020; 10: 16441674. 10.1007/s13346-020-00806-4

RYu, YMai, YZhao, YHou, YLiu, JYang. Targeting strategies of liposomal subunit vaccine delivery systems to improve vaccine efficacy. J. Drug Target. 2019; 27: 780789. 10.1080/1061186X.2018.1547734

XDu, JWang, QZhou, LZhang, SWang, ZZhang, et al Advanced physical techniques for gene delivery based on membrane perforation. Drug Deliv. 2018; 25: 15161525. 10.1080/10717544.2018.1480674

ABolhassani, BSJafarzade, GMardani. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides. 2017; 87: 5063. 10.1016/j.peptides.2016.11.011

10 

SShahbazi, ABolhassani. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines. Int. Immunopharmacol. 2018; 62: 170180. 10.1016/j.intimp.2018.07.006

11 

KKardani, AMilani, SHShabani, ABolhassani. Cell penetrating peptides: the potent multi-cargo intracellular carriers. Expert Opin. Drug Deliv. 2019; 16: 12271258. 10.1080/17425247.2019.1676720

12 

KHoffmann, NMilech, SMJuraja, PTCunningham, SRStone, RWFrancis, et al A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery. Sci. Rep. 2018; 8: 16. 10.1038/s41598-017-17765-5

13 

HXia, XGao, GGu, ZLiu, QHu, YTu, et al Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int. J. Pharm. 2012; 436: 840850. 10.1016/j.ijpharm.2012.07.029

14 

JYang, YLuo, MAShibu, IToth, MSkwarczynskia. Cell-penetrating peptides: Efficient vectors for vaccine delivery. Curr. Drug Deliv. 2019; 16: 430443. 10.2174/1567201816666190123120915

15 

FMilletti. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today. 2012; 17: 850860. 10.1016/j.drudis.2012.03.002

16 

JRMaiolo, MFerrer, EAOttinger. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim. Biophys. Acta Biomembr. 2005; 1712: 161172. 10.1016/j.bbamem.2005.04.010

17 

SFutaki. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv. Drug Deliv. Rev. 2005; 57: 547558. 10.1016/j.addr.2004.10.009

18 

FMadani, SLindberg, ÜLangel, SFutaki, AGräslund. Mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys. 2011; 2011: 110. 10.1155/2011/414729

19 

AGautam, MSharma, PVir, KChaudhary, PKapoor, RKumar, et al Identification and characterization of novel protein-derived arginine-rich cell-penetrating peptides. Eur. J. Pharm. Biopharm. 2015; 89: 93106. 10.1016/j.ejpb.2014.11.020

20 

KKardani, ABolhassani. CPPsite 2.0: An available database of experimentally validated cell-penetrating peptides predicting their secondary and tertiary structures. J. Mol. Biol. 2020; 166703 10.1016/j.jmb.2020.11.002

21 

ZLiu, YCui, ZXiong, ANasiri, AZhang, JHu. DeepSeqPan, a novel deep convolutional neural network model for pan-specific class I HLA-peptide binding affinity prediction. Sci. Rep. 2019; 9: 794 10.1038/s41598-018-37214-1

22 

JTang, JFu, YWang, BLi, YLi, QYang, et al ANPELA: analysis and performance assessment of the label-free quantification workflow for metaproteomic studies. Brief Bioinformatics. 2020; 21: 621636. 10.1093/bib/bby127

23 

YLi, MNiu, QZou. ELM-MHC: an improved MHC identification method with extreme learning machine algorithm. J. Proteome Res. 2019; 18: 13921401. 10.1021/acs.jproteome.9b00012

24 

JYin, WSun, FLi, JHong, XLi, YZhou, et al VARIDT 1.0: variability of drug transporter database. Nucleic Acids Res. 2020; 48: D1042D1050. 10.1093/nar/gkz779

25 

LChen, CChu, THuang, XKong, YDCai. Prediction and analysis of cell-penetrating peptides using pseudo-amino acid composition and random forest models. Amino Acids. 2015; 47: 14851493. 10.1007/s00726-015-1974-5

26 

HTang, ZDSu, HHWei, WChen, HLin. Prediction of cell-penetrating peptides with feature selection techniques. Biochem. Biophys. Res. Commun. 2016; 477: 150154. 10.1016/j.bbrc.2016.06.035

27 

BLiu, JChen, MGuo, XWang. Protein remote homology detection and fold recognition based on Sequence-Order Frequency Matrix. TCBB. 2017; 16: 292300. 10.1109/TCBB.2017.2765331

28 

KKardani, ABolhassani. Vaccine development against SARS-CoV-2: From virology to vaccine clinical trials. Coronaviruses. 2020; 1: 113.

29 

EKWabalo, ADDubiwak, TSGizaw, UGKotu. Role of structural and functional proteins of SARS-COV-2. GSC. Biol. Pharm. Sci. 2020; 12: 117129.

30 

JMFreire, ASVeiga, IRego de Figueiredo, BGde la Torre, NCSantos, DAndreu, et al Nucleic acid delivery by cell penetrating peptides derived from dengue virus capsid protein: design and mechanism of action. FEBS. J. 2014; 281: 191215. 10.1111/febs.12587

31 

MRhee, PDavis. Mechanism of uptake of C105Y, a novel cell-penetrating peptide. J. Biol. Chem. 2006; 281: 12331240. 10.1074/jbc.M509813200

32 

MCMorris, JDepollier, JMery, FHeitz, GDivita. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 2001; 19: 11731176. 10.1038/nbt1201-1173

33 

SKadkhodayan, ABolhassani, SMSadat, SIrani, FFotouhi. The efficiency of Tat cell penetrating peptide for intracellular uptake of HIV-1 Nef expressed in E. coli and mammalian cell. Curr. Drug Deliv. 2017; 14(4): 536542. 10.2174/1567201813666161006114448

34 

GElliott, PO’Hare. Intercellular trafficking and protein delivery by a herpes virus structural protein. Cell. 1997; 88: 223233. 10.1016/s0092-8674(00)81843-7

35 

HChakraborty, SBhattacharjya. Mechanistic insights of host cell fusion of SARS-CoV-1 and SARS-CoV-2 from atomic resolution structure and membrane dynamics. Biophysical Chemistry. 2020; 106438 10.1016/j.bpc.2020.106438

36 

MMahajan, DChatterjee, KBhuvaneswari, SPillay, SBhattacharjya. NMR structure and localization of a large fragment of the SARS-CoV fusion protein: Implications in viral cell fusion. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2018; 1860: 407415. 10.1016/j.bbamem.2017.10.002

37 

MMahajan, SBhattacharjya. NMR structures and localization of the potential fusion peptides and the pre-transmembrane region of SARS-CoV: Implications in membrane fusion. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2015; 1848: 721730. 10.1016/j.bbamem.2014.11.025

38 

SKumar, VKMaurya, AKPrasad, MLBBhatt, SKSaxena. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virus Disease. 2020; 31: 1321. 10.1007/s13337-020-00571-5

39 

FWu, SZhao, BYu, YMChen, WWang, ZGSong, et al A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579: 265269. 10.1038/s41586-020-2008-3

40 

AGautam, KChaudhary, RKumar, ASharma, PKapoor, ATyagi, et al In silico approaches for designing highly effective cell penetrating peptides. J. Transl. Med. 2013; 11: 74 10.1186/1479-5876-11-74

41 

AGautam, KChaudhary, RKumar, GPRaghava. Computer-aided virtual screening and designing of cell-penetrating peptides In Cell-Penetrating Peptides 2015; 5969); Humana Press, New York.

42 

HTang, ZDSu, HHWei, WChen, HLin. Prediction of cell-penetrating peptides with feature selection techniques. Biochem. Biophys. Res. Commun. 2016; 477: 150154. 10.1016/j.bbrc.2016.06.035

43 

LWei, PXing, RSu, GShi, ZSMa, QZou. CPPred-RF: a sequence-based predictor for identifying cell-penetrating peptides and their uptake efficiency. J. Proteome Res. 2017; 16: 20442053. 10.1021/acs.jproteome.7b00019

44 

BManavalan, SSubramaniyam, THShin, MOKim, GLee. Machine-learning-based prediction of cell-penetrating peptides and their uptake efficiency with improved accuracy. J. Proteome Res. 2018; 17: 27152726. 10.1021/acs.jproteome.8b00148

45 

HGBoman. Antibacterial peptides: basic facts and emerging concepts. J. Intern. Med. 2003; 254: 197215. 10.1046/j.1365-2796.2003.01228.x

46 

RGautier, DDouguet, BAntonny, GDrin. HELIQUEST: a web server to screen sequences with specific α-helical properties. Bioinformatics. 2008; 24: 21012102. 10.1093/bioinformatics/btn392

47 

ELSonnhammer, GVon Heijne, AKrogh. A hidden Markov model for predicting transmembrane helices in protein sequences. InIsmb 1998; 6: 175182.

48 

GShankar, SArkin, LCocea, VDevanarayan, SKirshner, AKromminga, et al Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS. J. 2014; 16: 658673. 10.1208/s12248-014-9599-2

49 

AKuriakose, NChirmule, PNair. Immunogenicity of biotherapeutics: causes and association with posttranslational modifications. J. Immunol. Res. 2016; 2016: 118. 10.1155/2016/1298473

50 

JJCalis, MMaybeno, JAGreenbaum, DWeiskopf, ADDe Silva, ASette, et al Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput. Biol. 2013; 9: e1003266 10.1371/journal.pcbi.1003266

51 

SGupta, PKapoor, KChaudhary, AGautam, RKumar, GPRaghava. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013; 8: e73957 10.1371/journal.pone.0073957

52 

IDimitrov, IBangov, DRFlower, IDoytchinova. AllerTOP v. 2-a server for in silico prediction of allergens. J. Mol. Model. 2014; 20: 2278 10.1007/s00894-014-2278-5

53 

IDimitrov, LNaneva, IDoytchinova, IBangov. AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics. 2014; 30: 846851. 10.1093/bioinformatics/btt619

54 

KChaudhary, RKumar, SSingh, ATuknait, AGautam, DMathur, et al A web server and mobile app for computing hemolytic potency of peptides. Sci. Rep. 2016; 6: 13. 10.1038/s41598-016-0001-8

55 

ALamiable, PThévenet, JRey, MVavrusa, PDerreumaux, PTufféry. PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Res. 2016; 44: W449W454. 10.1093/nar/gkw329

56 

GJNabel. Designing tomorrow’s vaccines. N. Engl. J. Med. 2013; 368: 551560. 10.1056/NEJMra1204186

57 

YDong, TDai, YWei, LZhang, MZheng, FZhou. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct. Target Ther. 2020; 5: 14. 10.1038/s41392-019-0089-y

58 

SDhakal, GJRenukaradhya. Nanoparticle-based vaccine development and evaluation against viral infections in pigs. Vet Res. 2019; 50: 90 10.1186/s13567-019-0712-5

59 

JWallis, PKatti, AMMartin, THills, LWSeymour, DPShenton, et al A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response. Eur. J. Pharm. Sci. 2020; 152: 105456.

60 

MZhang, YHong, WChen, CWang. Polymers for DNA vaccine delivery. ACS Biomater. Sci. Eng. 2017; 3: 108125. 10.1021/acsbiomaterials.6b00418

61 

NKajiwara, NNomura, MUkaji, NYamamoto, MKohara, FYasui, et al Cell-penetrating peptide-mediated cell entry of H5N1 highly pathogenic avian influenza virus. Scientific Reports. 2020; 10: 13. 10.1038/s41598-019-56847-4

62 

HARydberg, MMatson, HLAmand, EKEsbjorner, BNordén. Effects of tryptophan content and backbone spacing on the uptake efficiency of cell-penetrating peptides. Biochemistry. 2012; 51: 55315539. 10.1021/bi300454k

63 

PAWender, DJMitchell, KPattabiraman, ETPelkey, LSteinman, JBRothbard. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. 2000; 97: 1300313008. 10.1073/pnas.97.24.13003

64 

CECaesar, EKEsbjörner, PLincoln, BNordén. Membrane interactions of cell-penetrating peptides probed by tryptophan fluorescence and dichroism techniques: correlations of structure to cellular uptake. Biochemistry. 2006; 45: 76827692. 10.1021/bi052095t

65 

MHällbrink, AFlorén, AElmquist, MPooga, TBartfai, ÜLangel. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta Biomembr. 2001; 1515: 101109. 10.1016/s0005-2736(01)00398-4

66 

HRäägel, MPooga. Peptide and protein delivery with cell-penetrating peptides In Peptide and Protein Delivery 2011; 221246; Academic Press.

67 

XQi, TDroste, CCKao. Cell-penetrating peptides derived from viral capsid proteins. Molecular Plant-Microbe Interactions 2011; 24: 2536. 10.1094/MPMI-07-10-0147

68 

JHabault, JLPoyet. Recent advances in cell penetrating peptide-based anticancer therapies. Molecules. 2019; 24: 927 10.3390/molecules24050927

69 

SJKwon, KHan, SJung, JELee, SPark, YPCheon, HJLim. Transduction of the MPG-tagged fusion protein into mammalian cells and oocytes depends on amiloride-sensitive endocytic pathway. BMC Biotechnology. 2009; 9: 73 10.1186/1472-6750-9-73